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Norway possesses the highest melanoma mortality rates in Europe, with the country experiencing 
a rapid increase in incidence rates since the turn of the century. Melanoma occurs due to a 
malignant transformation of melanin synthesizing cells known as melanocytes, and is the deadliest 
form of skin cancer. Malignant melanoma displays one of the highest propensities to metastasize 
to the brain, and the resulting melanoma brain metastases (MBM) has a staggeringly poor 
prognosis, regardless of contemporary treatment strategies.  
 
Novel treatment design is strongly focused on integrating information of brain microenvironment 
directed influence on MBM development, in association with that of the melanoma metastatic 
cascade process. The emergence of 3D in vitro models which incorporate patient derived 
tissues/cells and enable longitudinal measurements have provided great promise in catalyzing this 
integration process while reducing the dependence on animal experimentation. The discovery of 
nanotube-mediated membrane continuity, termed as tunneling nanotubules (TNTs), by the late 
Hans-Hermann Gerdes (may he RIP) has shifted the paradigm of conventional cellular crosstalk 
and has opened the floodgates on research investigating how these structures mediate tumor 
progression and survival. Furthermore, the existence of the blood brain barrier (BBB) represents 
a major obstacle for the delivery of anticancer drugs to treat BM in the central nervous system 
(CNS) and may even contribute to tumor invasiveness and migration. The main aim of this thesis 
was to develop in vitro 3D model systems to be used for studying interactions between MBM and 
the brain metastatic niche. 
 
In this thesis, we reported, for the first time, visual evidence and characterization of TNT 
interactions between MBM and normal human astrocytes (NHA) of the brain microenvironment. 
We achieved this through our establishment of an in vitro 3D TNT interaction model that can be 
used ideally from 8 to 32h to study TNT interactions between MBM and NHA. Our findings also 
indicated the use of TNT interactions by MBM cell lines to promote treatment resistance and cell 
survival. Furthermore, we established an in vitro 3D BBB model that can be used ideally for a 








1.1 Understanding Melanoma 
Melanoma is a potentially fatal skin cancer that arises in melanocytes, which are specialized skin 
cells responsible for producing the protective skin pigment melanin (Figure 1.1). The patient 
prognosis is very good at the early localized stages but a sharp decrease in survival rate is seen 
once patients get diagnosed with advanced or metastatic state of the disease 1. It is holistically 
distinguished based on the site of its presentation as cutaneous or non-cutaneous melanoma. 
Cutaneous melanoma is subclassified depending on its clinical and histological presentation 2.  
Although not as common, the development of melanoma can also occur at non cutaneous regions 
of the body, including genitourinary, gastrointestinal, nasopharyngeal and ocular sites. While 
melanoma accounts for only 1 percent of all skin cancers, the disease is responsible for around 
73% of all skin cancer related deaths 3. 
            
Figure 1.1 Composition of normal layers of the skin, location of major structures and cells. Figure 
taken from PDQ Cancer Information Summaries - NCBI 4 
 
1.2 Epidemiology, Incidence and Survival 
The incidence of melanoma has risen at a faster rate than almost any other cancer during the last 
50 years 5–7. According to the 2020 Melanoma Skin Cancer Report by the Global Coalition for 
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Melanoma Patient Advocacy, Norway possesses the second highest incidence rate per capita 
globally (1 in 1983 per capita squared)8, and remains as the highest in Europe (29.6 cases per 
100,000 people)9. The risk of getting melanoma increases with age. It is very rare for someone to 
get this cancer before puberty, but melanoma is the second most common cancer in the age group 
25-49 years, both among men and women. There were 32 women and 12 men who were diagnosed 
with melanoma before the age of 30 in 2019. 
 
This trend has been reflected in the increase of skin melanoma rates in both genders (16.9% in 
men and 12.9% in women) within the last 6 years 10. Furthermore, incidence rates are most 
pronounced in the oldest age groups (70 years and above) and speculated to be prevalent in 
populations of higher socioeconomic status and adverse suntanning tendencies10. Melanomas 
possess high propensities to metastasize to the brain 11 and remain one of the most recurrent 
intracranial tumors in adults 12. Brain metastases (BM) are a common complication in patients 
with cutaneous melanoma. If BM is left untreated, the median overall survival (OS) rate is less 
than 6 months 13. Figure 1.2 shows the incidence rates of skin melanoma cases in males and 
females of Norway in the period of 1990-2020. 
 
Figure 1.2 – Incidence rates of melanoma of the skin: Data shown are from Norway in the 
period of 1990 – 2020. Incidence graphs correspond to the left y-axis (rates per 100 000). Graphs 
are from the Cancer Registry of Norway 2020 10 
 
1.3 Etiology and Risk Factors  

















Melanoma is regarded as a multifactorial cancer, owing to the variety of risk factors implicating 
it. The rise in melanoma incidence has been linked to the increase in use of tanning beds, increase 
in sun exposure and deterioration of the protective ozone layer 3,14. The major risk factors of 
melanoma are either exogenous (externally or environmentally related) or endogenous (internally 
or genetically related) factors. Exogenous factors are easier to modify through changes in lifestyle, 
while endogenous factors are inherent patient characteristics, and therefore less modifiable (Table 
1.1).  
 
Table 1.1 Summary of exogenous and endogenous risk factors of melanoma 
Risk factors  
Exogenous Endogenous 
Indoor tanning 15–17 Genetics 18–20 
Ultraviolet exposure 21–23 Family history 24,25 
Medications 26,27 Socioeconomic status 28–30 
Welding 31–33 Nevi 34–36 
Smoking 37–39 Ethnicity 40–42 
 Age 43–45 
 Gender 46–48 
 Site of presentation 49–51 
 Immunosuppression 52–54 
 
Ultraviolet (UV) radiation transmitted at various wavelengths exhibit a range of transmission into 
the skin layers 55. UVC (200-290 nm in wavelength) is incapable of penetrating past the superficial 
skin layer, UVB (290-320 nm in wavelength) reaches the basal layer of the skin epidermis and 
UVA (320-380 nm in wavelength) exhibits the greatest degree of transmission through penetration 
of the dermis layer. Among these three types, UVB demonstrates high carcinogenicity and 
promotes the metabolization of specific photoproducts such as cyclobutane pyrimidine dimers and 
pyrimidine pyrimidone photoproducts 56.  Up to 65% of melanoma cases are linked with exposure 
to sunlight 57. A history of sunburn, especially from an early age, has also been indicated to 
increase the risk of the disease 58. Studies have also shown a correlation between melanoma and 
non-accustomed exposure to sun. This may provide an explanation for the high number of cases 




Other risk factors for developing melanoma include skin paleness, red or blond pigmentation in 
hair, the tendency to tan poorly and the amount of freckles 61. The acquiring of nevi (colloquially 
known as moles) has also been recognized as a risk factor, in individuals possessing a) more than 
50 acquired nevi b) over five dysplastic nevi c) nevi > 6 mm or d) large congenital nevi. The 
formation of nevi can also occur as a result of sun exposure and serves as an indicator of the effect 
of UV radiation 57,62.  8 – 12% of melanomas occur as a result of inherited genetics, 41% of which 
cases are due to mutations in the genes for cell cycle regulation, particularly in the p16 pathway 
63. Less frequent risk factors include immunosuppression, scar formation, exposure to chemicals 
and Marjolin’s ulcer 64.   
 
1.4 Classification, Grading and Staging 
Melanoma was recently classified by WHO into three classes based on the mutagenic changes that 
arise in their formation – a) melanomas etiologically related to cumulative sun damage (CSD), b) 
melanomas caused by other factors and c) melanomas of a nodular nature 65.  Melanomas 
associated with CSD include those which are spreading superficially, desmoplastic melanomas 
and lentigo maligna. Among these subtypes, superficially spreading melanoma is the most 
recognized for its early radial growth followed by vertical growth and subsequent entry into the 
dermis 66.  Melanomas not caused by CSD are also subclassified into acral, mucosal, uveal, 
spitzoid and melanomas originating from congenital and blue nevi. Nodular melanoma is 
characterized by its early proliferation vertically downwards into the skin 66. 
 
Grading is used to describe the morphological characteristics of the melanoma cells and the degree 
of abnormality. Table 1.2 below provides a general grading system for melanoma.  
 
Table 1.2 General grading system for melanoma 67 
Grading Description 
G1  Well differentiated, look like normal cells. Low grade  
G2  Moderately differentiated, look partially abnormal. Moderate 
grade.  
G3  Poorly differentiated and are abnormal. High grade.  




Staging represents the size of the primary tumor as well as the degree of spread within the body of 
the patient 68. The staging of melanoma is determined by the degree of thickness, ulceration and 
spread of the disease to lymph nodes and distal regions of the body 69. This information plays a 
major role in determining a patient’s prognosis upon time of diagnosis. It has been reported that 
survival rates are negatively affected by progression in tumor thickness and disease stage 70,71. The 
general staging of cutaneous melanoma is illustrated in Figure 1.3 below.  
 
Figure 1.3 Stages of cutaneous melanoma and corresponding degree of carcinogenesis 72 
 
Melanoma staging utilizes a tumor node-metastasis (TNM) system which differentiates tumors 
based on tumor thickness within the skin, number of distant metastases and frequency of metastatic 
nodes (Table 1.3). Stage 4 melanoma is the most lethal, with metastatic spread to multiple organs 
of the body (including the brain, liver and lungs) 73.  
 
Table 1.3 Melanoma staging and corresponding 5 year survival 74. 
Stage Description 5 Year Survival 
Stage 0  Melanoma in situ. Abnormal neoplasm confined to 
epidermis.  
-  
Stage I  Melanoma confined to the skin. Thickness of <1 mm2. Can 
be ulcerated (skin covering is broken open) or not.  
92-97%.  
Stage II  Melanoma is ulcerated, but not spreading. Thickness is 
from 1.01 mm to 4.0 mm.  
53-81%.  
Stage III  Melanoma has metastasized to either one or more lymph 40-78%.  
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nodes, or nearby skin.  
Stage IV  Melanoma has spread to internal organs, distant lymph 
nodes, or distant skin.  
15-20%.  
 
1.5 Biological Characteristics  
Melanocytic neoplasms usually range from benign lesions (melanocytic nevi) to their malignant 
counterparts (melanoma). They are primary situated in the epidermal-dermal junction of the skin 
and produce melanin. Mammalian melanin is distinguished into two groups based on color – 
eumelanin (brown black) and pheomelanin (yellow red) 75. Melanin (predominantly eumelanin) 
shields the skin from UVR by absorbing and redistributing UV energy and protecting genetic 
material present in the nuclei 76. Around 50-75% of UVR is absorbed by melanin 76, which reduces 
damage on the skin caused by sunburn 77, prevents abnormal thermoregulation 78 and minimizes 
tissue injury caused by reactive oxygen species (ROS) 79.  
 
1.6 Molecular Characteristics 
At the cellular level, cancer cells possess various “hallmarks” which enable them to, among others, 
evade apoptosis, grow limitlessly without growth factors, promote angiogenesis and metastasize 
80. These specific molecular advantages are critical to understand for the development of more 
targeted, personalized and robust therapies and consequentially, improved patient prognoses 81. 
Genetic mutations termed as “driver mutations” play a major role in inducing advantageous 
mutations which promote cellular proliferation and survival.  Driver mutations act on tumor 
suppressor genes (responsible for regulating cell replication and division) and proto-oncogenes 
(contributes to cell growth) to promote genetic instability. This sets off a chaotic cascade 
promoting further mutations, unregulated cell growth and sustained tumorigenesis. Melanoma 
possesses the highest mutation frequency among all recorded cancers 82,83, and its pathophysiology 
incorporates several gene signaling pathways which promote disease growth and proliferation. The 
following subsections expound the three most crucial oncogenic signaling pathways implicated in 




Figure 1.4 Overview of the three major pathways exploited by the melanoma metastatic process 
- Ras/MAPK, PI3K/AKT and WNT signaling pathways, as well as crosstalk between pathways. 
Ras/MAPK pathway: Ligand binding activation of receptor tyrosine kinase (RTK) promotes the 
activation of small GTPase Ras which then promotes the signal across the MAPK proteins (Raf, 
MEK 1/2 and ERK 1/2) which results in nuclear transcription of cell proliferation and survival 
genes. PI3K/Akt pathway: Activation of the AKT pathway through RTK ligand binding initiates 
PI3K proteins to promote the conversion of PIP2 to PIP3, which enables phosphorylation of 
protein kinase B (Akt). AKT signaling regulates numerous pathways, namely GSK3β production 
in cell cycle and glucose metabolism processes, mTORC1 in cell growth, protein synthesis and 
angiogenesis and FOXO1 proteins in apoptosis, DNA repair processes and cell metabolism. The 
ligand activated release of mTORC2 further promotes PI3K pathway activation. AKT regulation 
of the tuberous sclerosis complexes (TSC 1/2) allows for the regulation of Ras homolog enriched 
in brain (Rheb) proteins which influence mTORC1 activation. GSK3β and TSC 1/2 signaling 
coordinate with each other to regulate cell development mechanisms. WNT pathway: WNT 
proteins bind to its specific receptor Frizzled (FRP) and LRP proteins which form a complex that 
recruit Dishvelled (DVL) proteins which inhibits β-catenin phosphorylation in the β-catenin 
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complex and thus ensuing β-catenin stabilization. Release of stable β-catenin activates nuclear 
processes for cell growth and proliferation. β-catenin complex consists of the proteins Axin, 
GSK3β, Casein kinase 1 (CK1), adenomatous polyposis coli (APC) and β-catenin. The MAPK 
pathway crosstalks with the PI3K pathway through GSK3β regulation by Ras proteins. The PI3K 
pathway crosstalks with WNT pathway through AKT regulation of GSK3β in the β-catenin 
complex, which further dictates the release of stable β-catenin. Activated PTEN proteins inhibit 
both the formation of AKT and β-catenin. 
 
1.6.1 The MAPK signaling pathway 
Studies show that melanomas commonly possess mutations in proteins in the mitogen-activated 
protein kinase (MAPK) signaling pathway. This pathway is activated either by receptor tyrosine 
kinase (RTK) binding to site specific ligands or integrin adhesion of the cell membrane and 
extracellular matrix 84. Transmission of signals along this pathway utilizes Rat sarcoma (Ras) 
GTPase, with highest level of activity occurring in the inner leaflet of the plasma membrane 85. 
The most common somatic mutations in the MAPK pathway are activating point mutations found 
in the b-Raf murine sarcoma viral oncogene homolog (BRAF, around 50% of melanomas) 86. 
Being a member of the RAF protein family, BRAF plays a major role in regulating cell growth 
and proliferation in response to growth factor signaling 87. 97% of BRAF mutations occur in codon 
600 of the gene, where an amino acid substitution in the activation segment within the kinase 
domain forms a constitutively active form of the protein. A large majority of these mutations (90%) 
are compromised of the V600E missense mutation, that converts valine to glutamic acid, and 
contributes to around half of all metastatic melanoma cases 88,89. The V600K is the second most 
common mutation, with the conversion of valine to lysine. Intriguingly, BRAF V600E mutations 
are also exhibited in 68% of benign nevi, but due to the stability of their formation, it is suspected 
that these mutations might not contribute to melanoma carcinogenesis 90. The signaling cascade 
results in the phosphorylation of MEK1/2 dual-specificity protein kinases and subsequent 
activation of ERK1 and ERK2 MAPKs, which are capable of translocating into the nucleus to 
regulate a range of transcription factors 91,92. 60 – 70% of vertically growing lesions and metastatic 
melanoma possess BRAF mutations, indicating the effect of this oncogenic mutation on the cancer 






1.6.1.1 NRAS  
The second most prevalent mutations occurring in melanoma cases involve the neuroblastoma Ras 
viral oncogene homolog (NRAS). Mutations have been reported in 15-20% of melanoma cases, 
with 98% of activating mutations detected in the Q60/61 and G12/13 codons (Ras isoforms) 94,95. 
NRAS is an important constituent of the MAPK pathway, and is a member of the Ras protein class 
responsible for modulating Raf protein activity 89,96. Although this means that both these 
oncogenes operate within the same pathway, concurrent mutations in both oncogenes are rarely 
reported in the same patient. This suggests that BRAF and NRAS mutations may operate mutually 
exclusive of each other 97–99. Patients possessing NRAS mutations show manifestations of thick 
vertical growth tumors, most likely owing to the increased cell proliferation rates instigated by the 
mutation process 94.  Furthermore, NRAS driven activations affect both the phosphoinositide 3-
kinase (PI3K) and MAPK signaling pathways, making the design of effective NRAS inhibitors 
challenging in the development of targeted therapies. 
 
1.6.2 The PI3K signaling pathway 
Mutations in the phosphatidylinositol-3-kinase (PI3K) signaling pathway are often found during 
the course of melanoma progression 100,101. This pathway is strongly involved in cell proliferation 
and survival and also promotes cell viability through inhibition of apoptosis 102. Oncogenic Ras is 
involved in MAPK signaling and also acts as a positive upstream regulator of the PI3K pathway 
103. The most frequent mutation observed is an inactivation mutation in the phosphatase and tensin 
homolog (PTEN) tumor suppressor gene. PTEN is a critical negative regulator of protein kinase 
B (AKT) by preventing its phosphorylation, with subsequent inhibition of the PI3K pathway. 
Furthermore, it also plays a role in targeting and dephosphorylating proteins such as focal adhesion 
kinase (FAK), which results in the inhibition of focal adhesion development and a reduction in 
cellular migration 104. A mutation in PTEN leads to a competitive growth advantage that promotes 
tumor growth and metastasis. Mutational changes in PTEN account for 10% of primary 
melanomas 105,106. While former analyses of melanoma tumor samples have identified a rate of 
around 3% PI3K missense mutations 107,108, there are multiple avenues for the PI3K pathway to be 
hyperactivated (including NRAS activation) 109. Furthermore, PTEN mutations are frequently 
associated with BRAF mutations, causing simultaneous upregulation in both the PI3K and the 
MAPK pathways 110. Therefore, hyperactivation of this pathway often results in disease resistance 
to chemotherapy and radiation treatment 102. Studies have shown high rates of both BRAF and 
PTEN mutations occurring concomitantly in cases of melanoma, with NRAS mutations (described 
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in 1.5.4.1) occurring mutually exclusive to both former mutations 111.  
 
1.6.3 The WNT signaling pathway  
The WNT signaling pathway plays a major role in regulating crucial cellular processes, including 
cell proliferation, migration and fate determination 112. The complexity of this pathway is 
emphasized by the numerous cell-signaling cascades activated upon ligand binding 113. The 
primarily well recognized pathway is adherens junction molecule β-catenin dependent, and is 
involved in the accumulation and translocation of β-catenin into the nucleus to initiate WNT target 
gene expression (including upregulation of c-MYC, ZEB-1 and cyclin D1 genes) 114,115. These 
genes promote cell proliferation and cell cycle progression, as well as act in the inhibition of E-
cadherin expression in a wide range of cancers including melanoma 116–118. Abnormalities in WNT 
pathway activation is regarded as one of the major instigators of melanoma development, with 
aberrant signaling speculated to affect different stages of tumor progression 119. β-catenin 
dependent WNT signaling has been seen to operate synergistically with the MAPK signaling 
cascade, cumulatively contributing to melanoma formation and pathogenesis 120. Studies have also 
provided evidence of tumor metastasis promotion during the activation of non-canonical WNT 
signaling pathways 121–123. The impact of WNT signaling in melanoma is highly complex and 
involves the coordinated expression and distinctive activation of several intracellular molecules 
and interacting pathways through progressive stages of the disease. As such, the precise functions 
of the WNT pathways in melanoma remain to be completely elucidated.  
 
1.6.4 Other mutations and processes 
1.6.4.1 NF 1 
The tumor suppressor gene Neurofibromin (NF1) undergoes inactivating mutations in about 15% 
of cutaneous melanomas and are associated with 50% of BRAF/NRAS wild type tumors 124–126. 
NF1 is a GTPase activating protein which functions as a negative regulator within the MAPK 
pathway to promote the hydrolysis of RAS-bound GTP to inactive GDP-bound RAS 127–129.  
 
1.6.4.2 p53 
The tumor suppressor gene p53 regulates DNA repair and apoptosis and is implicated in several 
human malignancies, including prostate, colorectal, breast and lung cancer (36.1% of all cancers) 
130–133. It is activated during DNA damage or cell stress and induces cell death. While its role is 
disputed, there is a varying prevalence of p53 mutations in immunohistochemical analyses of 
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melanoma, reporting altered expression rates from as low as 11% to as high as 85% 134–136. 
Regardless of this fluctuating range, melanoma cells which express resistance to gamma radiation 
and chemotherapy often indicate an improper functioning of p53.  
 
1.6.4.3 Exosomes and vesicular trafficking 
Studies have provided increasing evidence of altered vesicular trafficking in cases of melanoma 
137,138. This includes the release of exosomes, a class of cell derived extracellular vesicles 
originating from endosomes and serving as carriers of 40-150 nm size biomolecules between 
virtually every cell type within the body and the extracellular environment 139,140. The primary role 
of exosomes is intercellular communication, and they possess a wide range of cellular constituents 
including lipids, proteins, DNA, mRNA and miRNA 141. The role of exosomes has been identified 
in immune regulation, intercellular protein and gene exchange, therapy response regulation and 
melanoma progression 142. Non canonical WNT signaling has been heavily linked with pro-
angiogenic and immunosuppressive responses via exosome release processes in malignant 
melanoma cells 143,144. Furthermore, the transfer of miRNAs and proteins via exosomes to a wide 
range of cell types including endothelial cells, bone marrow progenitor cells and fibroblasts 
indicate their involvement in the crosstalk between melanoma cells and the microenvironment 145. 
Further investigation in this area could provide vital information of exosome contribution in the 
promotion of melanoma proliferation and invasiveness.  
 
1.7 The Brain Metastasis Process 
Around 50% of melanoma patients with metastatic disease exhibit spread to the brain, a number 
that rises to 73-90% at autopsy 146–148. Metastasis to the brain occurs in a series of steps termed the 
“metastatic cascade”, the successful completion of which results in the formation of metastatic 
lesions within the brain (Figure 1.5). The process is initiated by the primary tumor, which 
promotes angiogenetic factors to establish a blood supply in the host organ for the transfer of 
oxygen and metabolic components for tumor growth. This is followed by the invasion and cellular 
migration across the basement membrane and intravasation into surrounding blood vasculature, 
survival in the circulation system, extravasation from the vasculature into the brain parenchyma 
and finally, colonization and formation of solid tumors in the brain 149. The mechanism of local 
invasion of tumor cells heavily relies on the epithelial to mesenchymal transition (EMT) process, 
in which cells readapt themselves to obtain improved migration and invasive properties 150,151. 
Epithelial tumor cells initiate the EMT process by acquiring motility and breaking down the 
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underlying basement membrane and extracellular matrix (ECM) proteins, permitting their entry 
into the blood or lymphatic circulation. This transition is mediated by a variety of factors, including 
cytokines, hypoxia or the release of growth factors 152. However, the survival rate of tumor cells 
in the circulation cells is low, owing to the action of the immune system, the shear forces applied 
on the cells as well as the lack of adhesion signaling systems 153. Melanoma cells with the potential 
for brain colonization develop mechanisms which allow them to survive in the circulation and 
reach the brain, where they attach to endothelial cells in the microvasculature and extravasate 
through the BBB 154. These tumor cells proceed to interact with the brain microenvironment 
(BME) to promote neoangiogenesis, vessel co-option (migration of tumor cells along the pre-
existing vasculature to obtain higher access to nutrients) 155 and perivascular proliferation 156. The 
steps in the process culminate in metastatic colonization and steady transition from micro- to 
macrometastases. It is now recognized that tumor cells from different primary cancers possess a 
tropism to specific tissue, enabling them to “home” to various secondary organs 157. This reflects 
the “seed and soil” therapy of Paget 158, who first visualized the metastatic process as a non-random 
process involving specific tumor cell clones (the “seed”) which possess specific affinity for a 
particular microenvironment existing in target organs (the “soil”). The mechanisms directing brain 
metastasis remain to be fully elucidated, especially with regard of the association of the brain 




Figure 1.5 Steps in the “metastatic cascade” during tumor metastasis to the brain. 1. Tumor 
establishment – Formation of the primary tumor in the primary organ. 2. Migration – Invasion of 
primary tumor cells across the basement membrane and intravasation into surrounding blood 
vasculature. 3. Vascular arrest by size exclusion – Survival of tumor cells in the circulation is 
determined by their size (relative to blood vessels) and resistance to shear forces in the 
bloodstream. 4. Active extravasation – Movement of surviving tumor cells into the brain 
parenchyma. 5. Perivascular proliferation and neoangiogenesis – Interaction of tumor cells with 
the BME to promote formation of new blood supply and proliferation of secondary tumor in the 
metastatic niche. Figure adapted from El Rassy, E.; Botticella, A.; Kattan, J.; Le Péchoux, C.; 
Besse, B.; Hendriks, L. Non-Small Cell Lung Cancer Brain Metastases and the Immune System: 
From Brain Metastases Development to Treatment. Cancer Treatment Reviews. W.B. Saunders 
Ltd July 1, 2018, pp 69–79. https://doi.org/10.1016/j.ctrv.2018.05.015. 
 
1.8 Transformation of the Brain Microenvironment  
The brain microenvironment is a mosaic possessing extracellular matrix components and a number 
of specialized cell types, namely astrocytes, endothelial cells, neurons, microglia, 
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oligodendrocytes and pericytes 159. Astrocytes are specialized glial cells which out populate 
neurons in the BME around fivefold. They are characterized by their contiguous spread across the 
CNS and respond to injury and pathogenesis via a process called reactive astrogliosis, now a 
pathological hallmark detected in structural lesions present in the CNS 160.  
 
Endothelial cells possess tight junctions and are highly prevalent across the BBB, forming the 
perimeter in the network of blood capillaries spread across the brain 161. While mechanisms of 
metastatic cell binding to endothelial cells are poorly understood, the process is speculated to be 
regulated by interactions between tumor cells and endothelial cell adhesion molecules 162,163. The 
components in the brain microenvironment regulate physiological homeostasis and strategizes the 
feedback to pathological, including metastatic, dysregulations. Intercellular communication plays 
a major role in directing the heterotypic and homotypic interactions within the BME. Studies have 
shown that tumor cells induce cell reprogramming in the BME, allowing the formation of 
hospitable “pre metastatic niches” which promote metastatic growth 164,165. Primary tumors release 
a multitude of growth factors, soluble factors, extracellular vesicles (exosomes), cytokines, 
proteases and miRNAs to stimulate angiogenesis and tumor proliferation in the premetastatic niche 
166–168. However, it is still unclear as to how these microenvironment changes promote metastatic 
seeding and tumor proliferation.  
 
Astrocytes (50% of brain cell population) and microglia (10 – 15% of brain cell population) have 
been recognized to express inflammatory cytokines and growth factors associated with promoting 
brain metastases 169. The CNS is considered a distinctive organ for BM due to its lacking of 
lymphatic vessels and its enclosure by the BBB 170. Recent research has identified the existence of 
meningeal lymphatic vessels which mediate communication between the brain and the immune 
system 171. Metastasizing cells arrive by the arterial blood supply and attach to the endothelial 
tissue around blood capillaries, preceding the invasion of the BBB 172. Metastatic colonization in 
the pre metastatic niche concludes the formation of the brain metastatic niche (the “prepared” brain 
microenvironment).  
 
1.9 The Blood-Brain Barrier (BBB) 
The BBB is composed of specialized endothelial cells lined by the basal lamina, astrocytic endfeet 
processes which interact with the capillary bed, pericytes and microglia 173. It restricts the free 
migration of substances such as solutes and cellular elements between the systemic circulation into 
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the neuronal tissue 174. The selective entry of the BBB permits the passage of a small group of 
substances, including lipid soluble molecules (such as oxygen, carbon-dioxide), compounds 
consisting of less than 8 to 10 hydrogen bonds and smaller than 400-500 Da. This greatly narrows 
down the entry of large molecule drugs (such as antibodies) and also the majority (98%) of small 
molecule drugs 175,176.  Several studies have already indicated the involvement of the BBB in the 
pathogenesis of several CNS disorders 177,178.  
 
The physiological architecture of the BBB is coordinated by several transport, physical and 
metabolic properties possessed by the endothelial cells, which in turn are regulated by interactions 
with various neural cells, immune perivascular macrophages and vascular cells. The function of 
the barrier depends on tight junction proteins (such as claudins, occludins and junctional adhesion 
molecules), which cooperate with each other to limit the passive diffusion of solutes (small ions 
and drug molecules) into the extracellular region of the CNS 179–181. Animal studies have provided 
evidence of the cooperation between endothelial cells and cells of the parenchyma, particularly 
astrocytes, to maintain the formation of the BBB. This implies that the BBB integrity is not 
intrinsically regulated by endothelial cells alone but also in association with cellular elements of 
the brain microenvironment 182. Astrocyte perivascular endfeet are situated in close proximity to 
cerebral microvessels, facilitating signaling crosstalk between astrocytes and endothelial cells and 
inducing tighter junction formation in the BBB 180. The BBB and its individual components are 




Figure 1.6 The physiological architecture of the blood-brain barrier (BBB) and its constituents 
(endothelial cells, astrocytes, basal lamina and pericytes), as well as surrounding coordinating 
cells (microglia, perivascular macrophages and interneurons). Figure taken from A Review on 




During the course of tumor progression, there is a disruption of the BBB, resulting in the formation 
of the blood tumor barrier (BTB) 183,184. Several studies have indicated an intervention by 
melanoma cells to adhere and impede brain endothelial cell interactions via the disruption of 
adherence junction proteins (claudin 5 and ZO-1) 185. This interference facilitates the 
transmigration of melanoma cells across the BBB. Furthermore, the release of proteolytic enzymes 
such as seprase (Fibroblast Activation Protein Alpha; FAP) and heparanase (HPSE1) aid in the 
infiltration of metastatic cells into the brain extracellular space 186,187. Treatment strategies have 
already been developed with the aim of temporary disruption of the BBB to facilitate improved 
drug delivery 188–191. These include hyperosmotic openings, radiotherapy, focused ultrasound 
incorporated with microbubble contrast agents, surface protein modulation, convection enhanced 
delivery, polymer wafers, carrier molecules and viral mediated delivery. However such strategies 
have expressed limited success, each with their own strengths and weaknesses, calling for more 
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effective model breakthroughs 192,193.  
 
1.10 Tunneling Nanotubules (TNTs) 
Tunneling nanotubes (TNTs) is a dynamic and novel route for inter- and intracellular 
communication. TNTs operate using mechanisms distinct from the secretion of signaling 
molecules or the transmission of signals across adjacent cells via gap junctions 194. Reported 
initially in the rat pheochromocytoma (PC12) cell line 195,196, TNTs are long range cytoplasmic 
channels utilized in direct cell to cell communication. By definition, they are recognized by three 
phenotypic criteria – they bridge a minimum of two cells, they possess F-actin and they do not 
come into contact with the substrate 197,198. Structurally, TNTs exhibit a variation of widths 
between 50 nm to 1000 nm, and they are less than 100 µm in length 199–201. Furthermore, they 
demonstrate membrane continuity via open ended or close ended (interposed gap junction) TNTs 
194,202,203.  
 
Figure 1.7 TNT and extracellular vesicle (EV) mediated intercellular communication and cargo 
transfer between donor and recipient cell. TNT cargo includes mitochondria, intracellular vesicles 
(inVs), lysosomes, viruses and viral genomes, lipid droplets and Ca2+ ions. EVs, namely exosomes 
and microvesicles, transfer nucleic acids, proteins and lipids between cells. Figure adapted from 
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Nawaz, M.; Fatima, F. Extracellular Vesicles, Tunneling Nanotubes, and Cellular Interplay: 
Synergies and Missing Links. Frontiers in Molecular Biosciences. Frontiers Media S.A. July 18, 
2017, p 50. https://doi.org/10.3389/fmolb.2017.00050 
 
The TNTs enable a rapid transfer of cellular cargo among a wide range of non-adjacent cells 202,204–
206 (Figure 1.7), and are found in several organisms and tissue types 199,207–214. TNTs are known 
to be involved in the transfer of several cytoplasmic molecules, including lysosomes, pathogens, 
proteins, miRNAs and mitochondria 215. Furthermore, they are implicated in cancer progression 
and metastasis, later stages of neurodegeneration, routes of spread for pathogenic agents and stem 
cell mediated regeneration and homeostasis 216,217. The earliest detection of TNTs in human 
primary cancel cells and solid tumors in vitro 199 were succeeded by the observation of thin tumor-
originating membrane tubes in vivo. The latter, termed as tumor microtubes (TMs), exhibited a 
greater length and diameter compared to TNTs observed in vitro 218. Intercellular communication 
by TNTs are speculated to contribute to tumor survival and progression, acting as spatial and 
specific communication conduits between signal directing and signal receiving cell membranes 
219,220.  
 
The presence of TNTs in cancer cells is well documented, and they have been reported in cell 
populations of glioblastoma, squamous cell carcinoma, prostate cancer, ovarian cancer, 
adenocarcinoma and osteosarcoma, among others. Furthermore, TNTs have also been detected in 
distinct tumor types from patient explants 221–224.  Cancer cells coordinate TNTs to form a network 
of communication between malignant cells (homotypic interactions) and TME cells (heterotypic 
interactions) 217. The potential role of TNTs in BM has however not been reported. Two models 
of TNT formation via cell-cell interactions in different cell types are currently recognized. The 
first model is termed the “cell dislodgement” model and proposes the presence of TNT formation 
between two adjacent cells as they move apart 225,226. The second model is termed as the “filopodia 
interplay” model and interprets TNT generation from active cellular protrusions initiating direct 
contact between neighbouring cells 227,228. 
 
1.11 Treatment Strategies of Melanoma 
In recent years, there have been advancements in both local and systemic therapy of melanoma. 
The complexity of the disease and the myriad of treatment options calls for melanoma BM patients 
to be evaluated within a multidisciplinary setting to enable personalized treatment. Such appraisal 
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requires an assessment of several factors including the molecular classification of the disease, BM 
frequency and size, patient performance status and information on prognostic groups. Improved 
treatment outcomes have pushed for effective treatment strategies which maintain patient quality 
of life while minimizing neurological toxicity.   
 
1.11.1 Standard treatment strategies 
Traditionally, the treatment of BM relies on surgery or radiotherapy in combination with 
chemotherapy. Surgical resection is commonly used in cases where the patients have solitary or a 
few metastasis, often localized adjacent to critical brain structures 229,230.  
 
Whole brain radiotherapy (WBRT) in combination with corticosteroids has also been considered 
a typical initial treatment for BM, with the flexibility of administration alone or post-surgery 231. 
However, the use of radiation treatment often results in neurocognitive decline 232.  
 
Stereotactic radiosurgery (SRS) involves the delivery of a focused single high dose of radiation by 
x-ray or gamma radiation. SRS has provided positive results, demonstrating a statistically similar 
outcome in overall patient survival to WBRT 233.  
 
1.11.2 Novel treatment strategies 
1.11.2.1 Immunotherapy 
Immunotherapy has emerged as a promising treatment of melanoma, which is highly immunogenic 
in nature and sometimes exhibit immune mediated spontaneous regression 234. The monoclonal 
antibody Ipilimumab is a cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitor which 
promotes cellular immunity and decreases tolerance to tumor associated antigens 235. As a result, 
this strengthens the immune response against metastatic melanoma tumors. Pembrolizumab and 
nivolumab (programmed cell death 1 [PD-1] inhibitors) are also monoclonal antibodies which 
have shown promise in treatment of asymptomatic melanoma BM and capable of initiating 
programmed cell death 236,237. However, while immunotherapy has demonstrated encouraging 
results, it is speculated that patients on steroids may not be responding to the therapy, and that they 
are at risk of developing extensive neurological symptoms 238.  
 
1.11.2.2 Inhibitors of proteins in the MAPK pathway 
1.11.2.2.1 MEK inhibitors 
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Trametinib received approval by the US FDA in 2013 for BRAFV600E or BRAFV600K positive 
unresectable or metastatic melanomas. Its mechanism emphasizes on the inhibition of MEK 
signaling pathways downstream of BRAF. However, a significant decrease in disease response 
has been reported in trametinib treatment against BRAF wild type melanomas and in patients who 
had already undergone BRAF inhibitor therapy 239.  
 
1.11.2.2.2 BRAF inhibitors 
The discovery of BRAF mutations in melanoma has paved the way for new avenues of therapy, 
using small molecule BRAF inhibitors (such as vemurafenib and dabrafenib). These drugs target 
the BRAF protein and clinical trials have shown increased survival. The implication of BRAF 
inhibitors in the MAPK pathway is highly characterized, as illustrated in the figure below (Figure 
1.8).  
 
Figure 1.8 BRAF and MEK inhibitor activity in the MAPK pathway (activated by RTK ligands). 
BRAF inhibitors act on mutated BRAFV600E to inhibit signal transduction to MEK 1/2. MEK 





The oral serine-threonine kinase inhibitor vemurafenib (PLX4032, RG7204) was one of the first 
mutant-specific inhibitors of BRAF, and it has been shown that cell lines possessing the 
BRAFV600E mutation are sensitive to the drug 240. The drug was approved by the U.S Food & Drug 
Administration (FDA) in 2011 for use in therapy of advanced stage melanoma, due to inhibitory 
effects on cell cycle arrest and induction of apoptosis 241. While research into BRAF specific 
inhibitors progresses 242, the antitumor activity of vemurafenib in melanoma BM models requires 
greater investigation and further clinical trial data than what has already established by in vitro 243 
and in vivo models 244,245. A concern in treatment is that the tumors develop resistance to 
vemurafenib, around six months after initiation of therapy 246–249. Thus, current therapy strategies 
combine vemurafenib with other targeted therapies to provide more effective treatment. Currently, 
combined therapies using vemurafenib and immunotherapy agents atezolizumab and cobimetinib 
are being evaluated 250. 
 
Dabrafenib (GSK2118436) is a selective inhibitor which has exhibited strong treatment outcomes 
as a single agent in patients possessing BRAF mutated advanced melanoma. However, resistance 
to this drug is also developed after about 6 months of treatment 251.  Combination therapy of 
dabrafenib with the MAPK/MEK inhibitor trametinib was approved by the US FDA in 2018 has 
shown more positive results 252–254 (Table 1.4).  Further, randomized phase 3 studies combining 
dabrafenib and vemurafenib yielded statistically significant treatment outcome in terms of overall 
survival (OS), progression-free survival (PFS) and overall response rate (ORR) in comparison 
with chemotherapy (Table 1.4). 
 
Primary and acquired treatment resistance is a significant challenge to the development of effective 
BRAF and MEK inhibitors (Figure 1.8B). Besides combination therapy, treatment development 
strategies have also focused on other signaling proteins (CRAF, ARAF), mutational changes in 
other major effector proteins and activating tyrosine kinase receptors to stimulate survival 
pathways 255. The paradoxical effect of BRAF inhibitors on BRAF-wild type cells was also an 
unexpected finding in the development of BRAF inhibitors 256.  
 
A summary highlighting the treatment outcomes of selected targeted therapy trials in BRAF-
mutant advanced melanoma is provided in the table below (Table 1.4). 
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Table 1.4 Treatment outcomes of selected targeted therapy trials in BRAF-mutant advanced 
melanoma (Adapted from 257).  





BRIM-3 Vemurafenib 13.6 6.9 57% 258,259 
Dacarbazine 9.7 1.6 9% 
BREAK-3 Dabrafenib 18.2 6.7 53% 260,261 
Dacarbazine 15.6 2.9 6% 
Combi-D Dabrafenib + 
trametinib 
 
25.1 11 69% 254 
Dabrafenib 18.7 8.8 53% 
Combi-V Dabrafenib + 
trametinib 
26.1 12.1 68% 262 
Vemurafenib 17.8 7.3 50% 
CoBRIM Vemiurafenib + 
Cometinib 
22.3 12.6 70% 263 
Vemurafenib 17.4 7.2 50% 
COLUMBUS Encorafenib + 
Binimetinib 
33.6 14.9 64% 264 
Vemurafenib 16.9 7.3 41% 
Encorafenib 23.5 9.6 52% 








The main aim of this Master thesis was to develop in vitro 3D model systems to be used for 
studying interactions between MBM and the brain metastatic niche. 
Six sub aims were defined for the work in this Master thesis: 
1) To culture the human MBM cell line H1, hTERT-immortalized normal human astrocytes 
(NHA) and hCMEC/D3 cerebral endothelial cells followed by sorting of cell lines for high 
expression of fluorescent protein. 
2) To optimize the cell number/ratio of the human MBM cell line H1 relative to hTERT-
immortalized normal human astrocytes (NHA) to achieve an evenly distributed monolayer 
coculture. 
3) To provide essential information in a “systems biology” approach, through the evaluation 
of possible TNT interactions between MBM and NHA using confocal microscopy. 
4) To treat cells in co-culture with anti-cancer drug vemurafenib (PLX4032) and evaluate 
treatment effect on TNT interactions. 
5) To establish an in vitro BBB model utilizing the Boyden Chamber technique. 






3. Materials and Methods 
 
3.1 Cell Lines   
The human melanoma brain metastasis cell line H1 used in this work was established in our 
laboratory from a patient biopsy obtained after surgery at Haukeland University Hospital, Bergen, 
Norway. Written consent was obtained from the patient prior to the collection of tumor tissue 
material. The collection of tumor material, generation of cell lines and cell line work have been 
ethically approved (Regional Ethical Committee Approvals no 2013/720 and 2020/65185). The 
H1 cell line harbors the BRAFV600E mutation, as described previously 148. BRAF mutation status 
of the H1 cell line was investigated via massive parallel sequencing of the tumor DNA, based on 
published protocols 265. H1_DL2 cells were generated in the laboratory by transducing H1 
melanoma cells with two lentiviral vectors encoding green fluorescent protein variant Dendra and 
Luciferase 266. Flow cytometric isolation of cells by green fluorescent protein (GFP) expression 
was performed (BD FACS Aria, Becton Dickinson, Franklin Lakes, NJ, USA). 
 
Both Normal Human astrocytes (NHA) and NHA dsRed were provided by Professor Per Øyvind 
Enger´s Research Group at The Department of Biomedicine, University of Bergen. NHA dsRed 
constitutes of human telomerase reverse transcriptase (hTERT)-immortalized human astrocytes 
(Applied Biological Materials Inc., Vancouver, Canada), transduced with red fluorescent protein 
(RFP) lentivirus gene expression vector (pLV[Exp]-Hygro-CMV>mCherry) expressing dsred 267. 
Positive cells were selected by flow cytometry. hTERT is an enzyme responsible for the elongation 
and maintenance of telomere length to regulate cell life span and cell replication potential. 
Telomerase reactivation is a distinctive feature of human germ line and most cancer cells, and 
prolongs the time taken for cells to progress to the senescence or apoptosis stage 268.  
 
Human blood-brain barrier cerebral endothelial cells (hCMEC/D3) were purchased from Merck 
Millipore (EMD Millipore, Temecula, USA) and have been extensively characterized for brain 
endothelial phenotype and is a model of human blood-brain barrier (BBB) function 269. hBEC 
lucGFP was generated in our lab by transducing hCMEC/D3 cells with Firefly luciferase-GFP 






3.2 Cell Cultures 
All cell lines were cultured in ALT-DMEM cell growth medium (Table 3.1). Heat inactivation of 
fetal calf serum was carried out by exposing the serum to a temperature of 56 ºC for 30 mins in a 
water bath. All cells were incubated in a standard tissue culture incubator at 37 °C, 100% humidity 
and 5% CO2. Cell culture work was performed under sterile conditions inside a laminar airflow 
hood, with working surfaces and equipment disinfected with 70% ethanol. The cell lines were 
incubated in T75 culture flasks (Nunc, Roskilde, Denmark) and tested for mycoplasma every 2nd 
month during the laboratory work described in this thesis. 
 
Table 3.1 Reagents in the ALT-DMEM cell growth medium  
Reagent Name Company 
ALT-DMEM   
   Dulbecco’s Modified Eagle Medium 
   10% heat inactivated newborn calf serum 
    
   5 mg/mL Plasmocin 
   2% L-glutamine 
   100 IU/mL penicillin 
   100 µL/mL streptomycin 
Sigma-Aldrich Inc., St. Louis, MO, USA 
Thermo Fischer Scientific, Waltham, MA, 
USA 
Invitrogen, Toulouse, France 
BioWhittaker, Verviers, Belgium 
BioWhittaker 
BioWhittaker 
1X PBS  
   10x Dulbeccos phosphate-buffered saline 
   Autoclaved MilliQ water 
Sigma-Aldrich Inc. 
Merck Millipore, Molsheim, France 
Trypsin – Versene Mixture (Trypsin   EDTA) BioWhittaker 
 
3.2.1 Thawing of cells 
The cell cryovial was removed from the nitrogen tank and thawed by rolling in warm hands or by 
placing in a water bath at 37 ºC. The cell suspension was then transferred using a pipette with filter 
tip to a 15 mL polypropylene centrifuge tube (Sarstedt, Nümbrecht, Germany) containing 5 mL 
cold cell growth medium and resuspended with gentle pipetting. After centrifuging the cells at 900 
rpm for 4 min, the medium supernatant was removed, and the cells were resuspended in 5 mL cold 
cell growth medium. The cells were then pipetted into desired culture flask and additional 
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prewarmed growth medium was added.  
 
3.2.2 Splitting of cells  
Splitting of H1 cells were carried out using a protocol established in the laboratory. The cells were 
prepared in standard T75 culture flasks (Nunc) and the cultures were split upon reaching around 
approximately 80% of confluency. The old growth medium was first removed from the cell culture 
and the cells were washed with sterile phosphate buffered saline (1XPBS) solution. The PBS was 
removed, and 2 mL prewarmed Trypsin EDTA solution was added to the cells before incubating 
for 3-5 mins at 37 °C, 100% humidity and 5% CO2.  Cell detachment was evaluated through 
observation under light microscope after incubation. Growth medium (5-8 mL) was then added to 
the cell culture before centrifuging the cell suspension solution at 900 rpm for 5 min. The medium 
supernatant was then removed, and the cell pellet was gently resuspended in the desired volume 
of prewarmed ALT-DMEM. The cell suspension was then transferred back to T75 culture flask 
containing appropriate volume of prewarmed cell growth medium. Both H1_DL2 and hBEC 
lucGFP cell lines were used for a maximum of 10 passages before being replaced. NHA dsRed 
cell lines were used for a maximum of 5 passages before being replaced.  
 
3.2.3 Freezing down of cells (Cryopreservation) 
The freezing solution was prepared by mixing Solution 1 and 2 in a 1:1 (Table 3.2). The solution 
was stored in the fridge (4 ºC) until use. 
 
Table 3.2 Reagents for Solution 1 and 2 in preparation of freezing solution 
Solution 1 (20% serum) Solution 2 (20% DMSO 
9 mL (9v) ALT DMEM 8mL (4v) 1xPBS 
1 mL (1v) Fetal Calf Serum 2mL (1v) 100% DMSO 
 
Cells for freezing down were first washed, trypsinized and centrifuged as described in 3.2.2. The 
medium supernatant was then removed, and the cell pellet was resuspended gently and thoroughly 
in a desired volume of freezing solution (1mL per 2 x 106 - 2.5 x 106 cells). 1 mL of cell suspension 
was then aliquoted per cryotube (Nunc) and cryotubes were appropriately labelled. The cells were 
kept in freezer (-80 ºC) for 24 hrs before being transferred to the nitrogen tank.  
 
3.2.4 Cell counting for in vitro experiments   
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Cell counting was carried out using an automated cell counter (The Countess™, Invitrogen, 
Oregon, USA). 1 mL of the cell solution was moved into an eppendorf PCR tube (Sarstedt, 
Nümbrecht, Germany). 20 µL of cell solution was placed on a strip of parafilm paper before being 
stained with an equal volume of trypan blue. The cell solution was pipetted into both chambers of 
a cell counting chamber slide before the slide was placed in the cell counter for quantitative 
analysis. The mean number of cells/mL in the cell solution was calculated using the mean value 
of two individual counts of live cells/mL from the cell counter. 
 
3.2.5 Preparation of two-dimensional cell cocultures  
Two-dimensional (2D) cell cocultures of H1_DL2 and NHA dsRed cells were prepared in 24 well 
plates (Nunc, Roskilde, Denmark). Initially, both cells were seeded (in seeding densities and ratios 
described in 3.3.1) on the same day and observed using a Nikon TE2000 inverted light microscope 
(Nikon Instruments Inc., NY, USA) after 24 hrs of incubation. It was seen that confluency of 
astrocytes was much lower relative to that of melanoma cells. To account for this, NHA dsRed 
cells were seeded 24 hrs prior to the seeding of H1_DL2 cells to allow for earlier surface adherence 
of astrocytes and consequently greater confluency. Non-uniform distribution of cells was 
minimized by adding the cell suspension to the plate dropwise and shaking the plate in a cross like 
pattern (forward-backward and left-right) three or four times. Care was taken when putting the 
plate back into the incubator by preventing any swirling or spiraling motion. 
 
3.3 Establishment of TNT Interaction Model 
The initial idea behind establishing the TNT interaction model was to determine if TNT formations 
were present in BM models in vitro, and if so, determine interactions between H1_DL2 and NHA 
dsRed cells in monolayer cocultures. This was followed by quantification of all types of TNT 
interactions (both homotypic and heterotypic) between the two cell populations and evaluation of 
any trends after coculture treatment with anticancer drugs.  
 
3.3.1 Determination of optimal cell seeding densities for confocal visualization 
Cells were passaged and counted prior to seeding in 24 well plates (Nunc). The chosen cell 
densities and coculture ratios for H1_DL2 and NHA dsRed cells are shown in Table 3.3. Cells 
were seeded in duplicates in the desired cell densities. 
 
Table 3.3 Cell seeding densities and corresponding ratios used in thesis 
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Number of H1_DL2 cells Number of NHA dsRed cells Coculture ratio 
2.5 x 104 2.5 x 104 1:1 
5 x 104 5 x 104 1:1 
7.5 x 104 7.5 x 104 1:1 
2.5 x 104 5 x 104 1:2 
5 x 104 2.5 x 104 2:1 
 
The cell plates were then incubated at 37 °C, 100% humidity and 5% CO2 for 24 hrs before being 
transferred to the IncuCyte Live Cell Imaging System (Essen BioScience Ltd. Hertfordshire, UK) 
for live visualization.  
 
3.3.2 Evaluation of coculture cell proliferation   
Cell proliferation was evaluated under the 20x objective of the IncuCyte Live Cell Imaging System 
(Essen BioScience Ltd.). Images were taken every 30 mins for 72 hr of four regions in each well 
preset by the system and the images taken every 2 hrs were evaluated for the study. Subsequent 
analyses were performed using the Basic Analyzer software module (Essen BioScience Ltd.) of 
the system. Each experiment was repeated three times. Images obtained were used to visually 
determine optimal seeding density for the visualization of TNTs. This was done based on three 
factors – the degree of cell confluency within field of view, the uniform distribution of cells within 
the monolayer plane and the frequency of visible interactions during the period of evaluation. 
Visualization periods with well-spaced uniform growth distribution of cells were opted for on the 
premise of evidence from existing studies that TNTs displayed large variation in length, differing 
between cell lines 203,270–277. Optimal confluency of cells was also a key parameter to achieve good 
conditions for TNT formation and existing studies have reported that high or low confluence of 
cells could impair TNT formations 278. Frequency of visible interactions was also an important 
factor to consider, since TNTs could form via a “cell dislodgement” mechanism where two cells 
initially in contact disassociate from each other with the attachment of membrane that develops 
into a TNT with cytoplasmic continuity between the interconnected cells. Images obtained from 
the system were used to establish a suitable timepoint for confocal visualization of cocultures at a 
cell density of around 60-70% confluency, uniformly distributed without forming clumps or 
aggregates, while displaying visible interactions between the cells.  
 
3.3.3 Hoechst staining of nuclei 
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Hoechst 33342 (Molecular Probes, Life Technologies) was prepared from stock solution by 
diluting stock concentration (10 mg/mL) to 4 µg/mL in prewarmed cell media to form Hoechst 
medium solution. All steps were carried out in the dark due to the photosensitivity of Hoechst 
dyes. Hoechst medium solution was stored wrapped in aluminum to prevent exposure of medium 
to light. Prior to confocal imaging, cells were seeded in µ-slide 4 well chambered coverslips (Ibidi, 
Gräfelfing, Munich) and the cell growth medium in wells was replaced with Hoechst medium 
solution and slide chambers were incubated for 1 hr at 37 °C, 100% humidity and 5% CO2.  
 
3.3.4 Imaging of TNT interactions  
The µ-slide 4 well chambered coverslips (Ibidi) were mounted on the holder of Dragonfly 505 
confocal spinning disk system (Andor Technologies, Inc., Belfast, Northern Ireland) equipped 
with a live-cell microscope incubation cage (Okolab, Pozzuoli, Italy) which maintained the 
coculture environment at 37 °C, 100% humidity and 5% CO2. All images were captured with the 
iXon 888 Life EMCCD camera within the confocal system. Images were captured during the 8th, 
24th and 33rd hrs after introduction of H1_DL2 cells to coculture (based on the timepoint results 
obtained from the IncuCyte experiments). The cell density for each cell line were based on the 
results obtained from the IncuCyte experiments (Table 3.3), taking into account the differences in 
surface areas between µ-slide chamber wells and the well plates. The images were analyzed using 
the FUSION imaging software (Andor Technologies, Inc.). Objectives were chosen to facilitate 
the visualization of possible TNT interactions while also allowing for an appropriate visualization 
of areas between cell bodies in the field of view.  For this study, 2x2 montages of 20x objective 
images were taken of each chamber. 4 40x images were then captured from each 20x objective 
image, using the montage as reference points. TNT interactions from H1_DL2 to NHA dsRed, 
H1_DL2 to H1_DL2, NHA dsRed to H1_DL2 and NHA dsRed to NHA dsRed in each 40x field 
of view were counted.  
 
Cell fluorescence was visualized using preset filter protocols on the confocal system for green, red 
and blue fluorescence. H1_DL2 cells were imaged using a 488 nm laser line at 5% intensity, 50 
ms exposure time, and a 525 nm filter. NHA dsRed cells were imaged using a 561 nm laser line at 
5% intensity, 50 ms exposure time, and a 600 nm filter. Hoecsht stained cell nuclei were imaged 
using a 405 nm laser line at 5% intensity, 50 ms exposure time, and a 442 nm filter. TNTs were 
defined according to the parameters mentioned in 1.7.2. They were distinguished from cytoplasmic 
bridges (cell protrusions which appear following cell division) by the absence of a midbody visible 
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by cytoplasmic staining. Confocal images were visualized in the 3rd dimension (X-Z plane) to 
evaluate TNT localization relative to the substratum. Z-stack images were taken at a step size of 1 
µm. Cells were counted per chamber via visible Hoechst viable cell nuclei staining. All confocal 
images were processed using IMARIS 9 image analysis software (Oxford Instruments, Abington, 
UK), including length and width measurements of TNTs. Results were tabled and presented in 
graphs of relative percentage numbers using GraphPad Prism 8 (GraphPad software, Inc., La Jolla, 
CA, USA).  
 
3.3.5 Evaluation of anticancer drug treatment in TNT interaction model 
The drug vemurafenib was purchased from Chemietek (Indianapolis, IN, USA). Vemurafenib was 
dissolved in dimethylsulfoxide (DMSO) and stock concentrations of 50 mM were stored at −20 
°C in aliquots prior to use. The final drug concentrations selected for evaluation of potential effects 
in the TNT interaction model were made in ALT DMEM (0.5, 0.8, 1 and 1.5 μM). Selection of 
vemurafenib drug concentrations was done based on monolayer viability drug assays previously 
conducted on the H1 cell line in our lab and also after consultation of scientific literature. Drug 
concentrations were added to the coculture systems of H1_DL2 and NHA dsRed 2 hrs prior to 
confocal visualization and drug effects on TNT interactions between both cell populations was 
quantitatively and qualitatively evaluated during the established timepoint results. 
 
3.4 Establishment of BBB Model 
The Boyden chamber technique, which is primarily employed for the study of cell migration and 
invasion, was used to develop our BBB model. Boyden chambers constitute of cylindrical cell 
culture inserts placed inside the wells of a 24 well plate. The inserts possess polycarbonate 
membrane bottoms, with defined pore sizes. The BBB model was designed with the focus of 
forming a contact coculture of hBEC lucGFP and NHA dsRed cells on opposing sides of transwell 
membranes within the Boyden chambers. 
 
3.4.1 Preparation of transwell inserts for seeding of human astrocytes and endothelial cells 
Two 24 well plates, each with 12 inserts (as marketed by Nunc, Roskilde, Denmark) were run and 
treated with the same conditions until the dye permeability assay. Inserts possessing 8 µm pore 
size membranes were used for the study, based on consultation with literature of in vitro BBB 




3.4.2 Coating of transwells  
The following reagents mentioned in Table 3.4 were used for the transwell coating and seeding 
process. 
 
Table 3.4 Materials for transwell coating and seeding 
Reagent Name Company 
Coating 
Poly-D-Lysine 0.1 mg/mL  Life Technologies Ltd., NY, USA 
Fibronectin 1 mg/mL Sigma Aldrich, St. Louis, USA 
Sterile distilled H20  
Serum Free Media (DMEM) (as described for ALT-DMEM in Table 3.1 
excluding 10% heat inactivated newborn calf 
serum) 
Seeding 
ALT-DMEM (as described in Table 3.1) 
1X PBS (as described in Table 3.1) 
Trypsin – Versene Mixture (Trypsin EDTA) Biowhittaker, Walkersville, USA 
 
Poly-D-Lysine solution (Life Technologies Ltd.) was diluted from 0.1 mg/mL stock concentration 
to 50 µg/mL working solution in 1XPBS prior to use. The basolateral side of the transwell inserts 
in the culture vessels (Figure 3.1) were coated with the working solution of Poly-D-Lysine (75 
µL/well). The culture vessel was incubated at room temperature for 1 hr. The Poly-D-Lysine 
solution was then removed, and the culture surfaces rinsed thrice with sterile distilled water (150 
µL/well). Care was taken to ensure the culture vessel was rinsed thoroughly since excess Poly-D-
Lysine solution is toxic to cells. The inserts were completely dried prior to the next step. 
 
Fibronectin solution (Sigma Aldrich) was diluted in serum-free growth medium from 1 mg/mL 
stock solution to 5 µg/cm2 based on coating protocol for the surface area of the inserts 280, with 
serum-free growth medium. The apical side of the transwell inserts in the culture vessel were 
coated with working solution of fibronectin (75 µL/well). The inserts were dried completely under 
the fume hood overnight. After drying, the inserts were rinsed once with 1XPBS and then allowed 
to dry in the hood for 1 hr. The culture vessel was then sealed with paraffin film and the vessel 





Figure 3.1 Coating of transwell insert membrane in basolateral and apical regions 
 
3.4.3 Seeding of cells in transwell inserts 
The inserts were inverted and placed upside down on their corresponding areas on the culture 
vessel lid. 80 µL of growth medium containing high and low concentrations of NHA dsRed cells 
(Table 3.5) was added to the basal side of the transwell inserts. The plate was placed overtop and 
the cells adhered for 4 hrs in the incubator at 37 °C, 100% humidity and 5% CO2. Care was taken 
to check the inserts periodically and rehydrate with cell growth medium when necessary, to 
prevent the formation of bubbles when the transwells were flipped back over. After 4 hrs, 500 µL 
of fresh warm growth medium was introduced to the bottom of the wells. The inserts were carefully 
inverted right side up in the culture vessel, with the basal and apical regions in their correct 
positions (Figure 3.2). 500 µL of cell growth medium with hBEC lucGFP cells were then seeded 
in the inserts. The inserts were incubated at 37 °C, 100% humidity and 5% CO2. After 24 hrs, the 
transepithelial electric resistance (TEER) over the inserts were measured.  
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*Cell seeding concentrations – hBEC lucGFP (2.2x105 cells/mL for 1.1x105 endothelial cells) Low 




Figure 3.2 Cell seeding positions of hBEC lucGFP and NHA dsRed in transwell insert 
 
3.4.4 Measurement of Transepithelial Electric Resistance (TEER) 
Prior to taking TEER measurements, the inserts were transferred to a fresh 12 well plate (Nunc). 
The inserts were kept in the 12 well plates throughout the duration of the experiments until the dye 
permeation assay was performed. Measurements were recorded using the EVOM3 instrument 
(World Precision Instrument, Hertfordshire, UK). The TEER electrodes were first soaked in bleach 
for 15 mins prior to use. The electrodes were then transferred to sterile MilliQ water for 2 mins 
before being left to dry. After drying, the electrodes were soaked in 70% EtOH for 2 mins before 
being left to re-dry. The plate type and name were set in the EVOM3 instrument before each 
measurement was recorded. Prior to reading, 1 mL of prewarmed growth medium was added to 
each well in two 12 well plates and labelled appropriately. The cell growth medium in the top of 
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the inserts was removed and replaced with 500 µL of fresh prewarmed cell growth medium. The 
inserts were then carefully transferred to the corresponding wells in the 12 well plates (as 
previously mentioned). The electrodes were soaked for 1 min in cell growth medium before TEER 
measurement. Measurements were taken every 24 hrs until the barrier resistance values began to 
significantly decrease. Blank measurements were first taken to prevent unintentional cell transfer 
via electrodes. Three readings were taken from each well from different positions. After all 
readings were measured, the values were saved and stored in the EVOM3 system. The culture 
vessels were then returned to the incubator. Care was taken to ensure that culture plates were not 
outside the incubator for longer than 20 mins during each counting. Once the readings were taken, 
electrodes were soaked in MilliQ water and 70% EtOH (for 2 mins each and allowed to dry in 
between). The probe was then returned to its holder and the EVOM3 was shut down. TEER 
measurement results were tabled and presented in graphs using GraphPad Prism 8 (GraphPad 
software, Inc). 
 
3.4.5 FITC dye permeability assay 
The dye used for the assay was Fluorescein isothiocyanate (FITC)-dextran (Sigma Aldrich, St. 
Louis, USA) with molecular weight- 4kDa. The dye was selected upon consultation with literature 
of classic Transwell chamber FITC assays 281–283. All steps of the process were carried out in the 
dark to account for dye photosensitivity. The dye permeability assay was performed on the 7th day 
of TEER measurement (Day 7) to offer time for barrier formation and repeated 7 days later (Day 
14).  
 
3.4.5.1 Preparation of standard curve and sample plate 
The FITC-dextran stock solution (2 mg/mL) was diluted in growth medium to 100 µg/mL prior to 
use. To facilitate sample collection, 500 µL of cell growth medium was added to the bottom of a 
fresh 24 well plate before transferring the inserts to the plate. The growth medium from the upper 
chamber of each insert was then replaced with 150 µL of FITC solution (100 µg/mL) and incubated 
for 2 hr in the dark at 37 °C, 100% humidity and 5% CO2. To the control plates, 150 µL of cell 
growth medium was added instead of FITC prior to incubation. Sufficient volumes of FITC 
dilutions (100 µg/mL, 33.3 µg/mL, 11.1 µg/mL, 3.7 µg/mL and 1.23 µg/mL) were prepared to 
allow for the generation of a standard curve for sample referencing. The standards were added to 
a 96 well plate in triplicates of 150 µL each. After incubation, triplicates of samples (150 µL each) 
were transferred from the lower chamber of each transwell insert to the 96 well plate. Dye 
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permeability assay results were tabled and presented in graphs using GraphPad Prism 8 (GraphPad 
software, Inc.). 
 
3.4.5.2 Measurement of dye permeability 
The 96 well plate was read at 485 nm excitation and 535 nm emission wavelengths by a plate 
reader (VictorTM 1420 fluorescence microplate reader, Perkin-Elmer Wallance Inc.). The lamp 
power was set at 2100 and readings were taken after 1 sec for each sample. The FITC-dextran 
transmigration across the inserts was calculated as percentage of the total volume added in the 
upper well of the inserts. Care was taken to rinse the cells gently twice with cell growth medium 
to remove excess FITC, in cases of the dye assay being repeated.  
 
3.4.6 Cell staining and fixing  
Cells on both sides of the inserts were stained at the end of the experiment and fixed for confocal 
microscopy. Culture medium was first removed from the top and bottom chambers of the 
transwells and the membranes rinsed twice with sterile 1XPBS. 500 µL of 4% paraformaldehyde 
(PFA) was added to the top and bottom chambers of the wells and the cells were fixated for 30 
mins at room temperature. PFA was then aspirated from both chambers and the inserts were rinsed 
twice with sterile 1XPBS. Sample plates were stored at 4 ºC with 500 µL 1XPBS in the top and 
bottom chambers until confocal microscopy was performed.   
 
3.4.7 Confocal imaging of BBB model barriers 
Prior to visualization, PBS was gently removed from both chambers and the insert membranes 
selected for confocal microscopy were carefully cut out using a sterile scalpel blade and placed 
within microscope coverslips for visualization. Coverslips were mounted on the holder of the 
Dragonfly 505 confocal spinning disk system (Andor Technologies, Inc.) equipped with a live-
cell microscope incubation cage (Okolab) which maintained the observation environment at 37 
°C, 100% humidity and 5% CO2. All images were captured with the iXon 888 Life EMCCD 
camera within the confocal system. Confocal images were taken at 20x objective and in both X-Y 
and X-Z planes. NHA dsRed cells were imaged using a 561 nm laser line at 5% intensity, 50 ms 
exposure time, and a 600 nm filter. hBEC lucGFP cells were imaged using a 488 nm laser line at 
5% intensity, 50 ms exposure time, and a 525 nm filter. Z-stack images were taken at a step size 





3.5 Transmigration of MBM cell line across BBB model 
Prior to assessing the transmigratory capacity of H1_DL2 cells across the BBB model, the barrier 
possessing the highest resistance (based on TEER measurement results) was introduced into the 
membrane inserts of a fresh 24 well plate (Nunc). hCMEC/D3 cells were seeded in place of hBEC 
lucGFP cells to facilitate H1_DL2 cell counting at the end of the experiment. The insert 
membranes possessed the same pore size (8 µm) as used in the previous experiments to maintain 
the characteristics of the BBB model. Control membrane inserts were also included with absence 
of BBB model layer. H1_DL2 cells were starved with serum free ALT-DMEM for 12 hrs prior to 
seeding in the membrane inserts. During the timepoint of highest barrier resistance (as determined 
by the TEER experiment), 4 seeding densities of serum starved H1_DL2 cells (5 x 103, 1 x 104, 5 
x 104 and 1 x 105 H1DL2 cells), each in 400 µL final volume, were seeded in the upper 
compartments of transwell inserts. 500 µL of ALT DMEM was added to the lower compartment 
of the inserts to serve as the chemoattractant. Figure 3.3 illustrates the transmigration assay setup. 
The plate was incubated for 24 hrs to allow for H1_DL2 migration across the BBB model and 
control inserts. After 24 hrs, serum free ALT DMEM and ALT DMEM were removed from both 
compartments and the cells were fixed by 4% PFA for 15 mins at room temperature. The PFA was 
then gently aspirated and the transwell inserts were washed twice with sterile 1XPBS to remove 
PFA excess and non-attached cells. The cells were then stained by incubation of the transwell 
inserts with Hoechst medium solution (of final concentration 10 µg/mL) for 15 mins at room 
temperature, protected from light. Following this, the inserts were washed twice with sterile 
1XPBS to avoid drying of membrane. Non-migrated H1_DL2 cells in the upper compartment of 
the insert membranes were carefully removed by gentle scrapping with cotton swabs. The 
membranes of each insert were then cut out using sterile scalpel blade and placed bottom facing 
up in microscope coverslips for confocal evaluation. The coverslips were mounted in the confocal 
microscope (Andor Technologies, Inc.) and the number of migrated H1_DL2 cells counted by 
evaluation of 10x images taken of the membrane. The results were calculated and presented in 





Figure 3.3 Transmigration assay setup using the established BBB model. The upper compartment 










4.1 All Cell Lines expressed Strong Fluorescent Protein Expression and Distinct 
Morphology  
Cell lines were cultured in ALT-DMEM and live cell images of untreated cells for all three tagged 
cell lines was obtained. All the images were captured while using the 10X and 20x objectives 
(Figure 4.1). 
  
   
  
  
   




   
  









Figure 4.1 Confocal images of untreated cell lines H1_DL2 (A), NHA dsRed (B) and hBEC 
lucGFP (C) using brightfield 10x (A1, B1, C1), fluorescence microscopy 10x (A2, B2, C2) and 
fluorescence microscopy 20x (A3, B3, C3). All images taken at 60-70% cell culture confluency 
Scale bar: 100 µm (10x) 50µm (20x)  
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Confocal images of cell lines (Figure 4.1) showed that the green fluorescence protein was 
functioning well in staining of both the H1_DL2 and hBEC lucGFP cell lines. Similar pictures 
were taken for the NHA dsRed cell lines with red protein fluorescence, and confirmed that the red 
fluorescence protein functioned as expected. The strong fluorescence obtained from all three cell 
lines indicated successful cell sorting of high fluorescent protein expression. 
 
Cell morphologically, the majority of H1_DL2 cells appeared triangular and elongated fusiform 
with cell bodies either independent or in attachment with neighboring cells. Some of the cells were 
more rounded, possibly indicating start of mitosis, while all cells tended to grow in monolayer 
adherent patches. 
 
The cell morphology of NHA dsRed cells revealed dense multipolar epithelial morphology with 
low stratification. The majority of the cells proliferated in thick adherent clusters with thick 
cytoplasmic extensions between clusters, and were highly distributed in all regions of the surface 
of the chamber well. 
 
Regarding the hBEC lucGFP cells, they showed spindle-shaped, elongated morphology 
characteristic of brain endothelial cells and non-overlapping cell growth upon formation of 
confluent monolayers.  
 
4.2 Equivalent Ratio (1:1) of 5 x 104 H1_DL2 and NHA dsRed yields Well-
spaced, Uniform Growth Distribution of Cells, optimal for 8-36 hrs of Confocal 




































Figure 4.2 IncuCyte images of H1_DL2 and NHA dsRed cocultures (cell seeding densities of 5 x 
104 in a 1:1 ratio) obtained across 4 timepoints (8 hr,12 hr,24 hr and 36 hr). Phase contrast images 
(A1, B1, C1, D1) and non-phase contrast images utilizing both green and red fluorescence 
channels (A2, B2, C2, D2). Phase contrast images were taken using 5% spectral unmixing (Basic 
Analyzer software module, Essen BioScience Ltd.) to better represent distribution of GFP and 
RFP fluorophores. Scale bar: 200 µm. The experiment was repeated 3 times with the most 




































IncuCyte evaluation revealed that a cell seeding density of 5 x 104 H1_DL2 and 5 x 104 NHA 
dsRed cells provided a suitable degree of cell confluency within the field of view, uniform 
distribution of cells within the coculture monolayer plane and optimal frequency of visible cellular 
interactions at an optimal timepoint range of 8-36 hrs. As observed in the images, both cell 
populations began to initiate visible cytoplasmic interactions at around 8 hrs post seeding 
(approximately 40% coculture confluency). At 12 hrs, there was a greater frequency of visible 
cytoplasmic interactions between both cell populations (approximately 50% coculture 
confluency), higher cell distribution and absence of clumping and aggregate formation. At 24 hrs, 
images revealed a time proportional rise in the number of cytoplasmic interactions and a greater 
uniformity of coculture distribution (approximately 80% coculture confluency). Furthermore, 
there was the detection of narrow cytoplasmic extensions between cell populations, especially in 
regions with lower cell distribution. A small degree of astrocyte clumping could also be visualized 
at this timepoint. At 36 hrs, images revealed high coculture confluency across the field of view, 
with reduced frequency of visible interactions between cell populations. There was a high degree 
of clumping and aggregate formation at this timepoint with high visibility of cell growth above the 




















4.3 H1_DL2 and NHA dsRed initiate Homotypic and Heterotypic TNT 
Interactions in Coculture 
TNT interactions were first visualized on the 40x objective during the 8th hr of the experiment, and 
then progressively detected during the 24th and 33rd hrs time points (Figures 4.3,4.4,4.5). 
Visualization was followed by quantification of TNTs (as described in Section 3.3.4) and the 
















Figure 4.3 Visualization of TNT interactions between H1_DL2 and NHA dsRed at the 8th hr using 
the 40x objective. A, B and C indicate 3 heterotypic TNT interactions between NHA dsRed cells 
(centre) and surrounding H1_DL2 cells. Width measurements – A (0.437 µm), B (0.572 µm) and 
































Figure 4.4 Visualization of TNT interactions between H1_DL2 and NHA dsRed at the 24th hr 
using the 40x objective. A indicates homotypic TNT interactions between 2 groups of NHA dsRed 
cells. B indicates a homotypic TNT interaction between 2 H1_DL2 cells. C indicates a heterotypic 
TNT interaction between a NHA dsRed cell and an H1_DL2 cell. D indicates a cluster of TNTs 






























Figure 4.5 Visualization of TNT interactions between H1_DL2 and NHA dsRed at the 33rd hr 
using the 40x objective. A indicates a heterotypic TNT interaction extending from a NHA dsRed 
to a H1_DL2 cell. B indicates a heterotypic TNT interaction extending from an H1_DL2 cell to a 
NHA dsRed cell. Scale bar: 25 µm 
 
Confocal visualization revealed both homotypic and heterotypic TNT interactions between 
H1_DL2 and NHA dsRed cells at the 8th hr of the study (Figure 4.3). TNTs visualized were less 
than 1 µm, and were clearly seen to travel over the substratum of the coculture to connect with 
other cells. Development of TNTs were more frequent at the 24th hr (Figure 4.4), with a higher 
frequency of TNTs from both H1_DL2 and NHA dsRed cells. Formation of TNT “clusters” were 
also detected during observation at this time point, emerging from both H1_DL2 and NHA dsRed 
cells but they were not included in the quantification process if they did not meet the TNT 
parameter of membrane continuity between two cells. The highest frequencies of homotypic and 
heterotypic TNT interactions were visualized at the 33rd hr (Figure 4.5) from both H1_DL2 and 
NHA dsRed cells. Slight alterations in cell morphologies were also detected at this timepoint, 
possibly indicating cell senescence. The majority of homotypic and heterotypic TNT interactions 
visualized at all 3 timepoints were seen to be initiated by NHA dsRed cells. This was later 
confirmed in the TNT quantification analyses (described in Section 4.3.1). Confocal visualization 
of the cocultures also confirmed successful Hoechst staining of cell nucleic acids, due to the clear 
detection of viable H1_DL2 and NHA dsRed cell nuclei which were visible as large blue dots in 
the images.  
 
4.3.1 NHA dsRed initiates higher relative percentage of homotypic and heterotypic TNT 











Figure 4.6 Quantification of TNT interactions between H1_DL2 and NHA dsRed during the 8 hr, 




from H1_DL2 and NHA dsRed cells over 3 time points of the study. B) Illustration of relative 
percentages of homotypic and heterotypic TNT interactions between H1_DL2 and NHA dsRed 
cells over 3 time points of the study. The experiment was carried out 2 times with the most 
representative results presented. 
 
The quantification of TNT interactions between H1_DL2 and NHA d.sRed during the 8th, 24th and 
33rd hrs of the study is shown in Figure 4.6. Quantification was carried out in two areas – the 
relative percentages of TNT interactions initiating from H1_DL2 and NHA dsRed cells over 3 
time points of the study and the relative percentages of homotypic and heterotypic TNT 
interactions between H1_DL2 and NHA dsRed cells over 3 time points of the study. Quantification 
results revealed a higher percentage of TNT interactions initiating from NHA dsRed cells across 
all 3 timepoints of the study (81 – 85%), compared to H1_DL2. The relative percentage of TNTs 
initiated by H1_DL2 stayed relatively constant through all 3 time points of the study (15 – 18%). 
The relative percentage of heterotypic TNT interactions by NHA dsRed increased noticeably 
between the 8th and 24th hrs of the study (from 38 to 46%), opposed to homotypic TNT interactions 
by NHA dsRed during the same time period. Furthermore, H1_DL2 cells exhibited a slight 
increase in homotypic interactions between the 8th and 24th hrs (from 2 to 8%).  
 
4.4 H1_DL2 initiates Higher Frequency of Homotypic and Heterotypic TNT 
Interactions at Increasing Vemurafenib Concentrations 
Vemurafenib (0.5, 0.8, 1 and 1.5 μM) were added to the coculture systems of H1_DL2 and NHA 
dsRed 2 hrs prior to confocal visualization and drug effect on homotypic and heterotypic TNT 
interactions between both cell populations was quantitatively and qualitatively evaluated at the 8th, 
24th and 33rd hrs. The confocal visualizations of the TNT model across all 4 drug concentrations 































Figure 4.7 Visualization of TNT interactions between H1_DL2 and NHA dsRed at the 33rd hr in 
the presence of 0.5 µM vemurafenib. Images captured on 40x objective. A indicates a homotypic 
TNT interaction extending from a H1_DL2 to a H1_DL2 cell. B indicates the slightly altered 































Figure 4.8 Visualization of TNT interactions between H1_DL2 and NHA dsRed at the 33rd hr in 
the presence of 0.8 µM vemurafenib. Images captured on 40x objective. A indicates homotypic 
TNT interactions extending from a H1_DL2 to neighboring H1_DL2 cells. B indicates the 
























Figure 4.9 Visualization of TNT interactions between H1_DL2 and NHA dsRed at the 33rd hr in 
the presence of 1 µM vemurafenib. Images captured on 40x objective. A indicates altered 
morphology of H1_DL2 cells with rough edges and granular membranes. B indicates extension of 






































Figure 4.10 Visualization of TNT interactions between H1_DL2 and NHA dsRed at the 33rd hr in 
the presence of 1.5 µM vemurafenib. Images captured on 40x objective. A indicates network of 
TNT interactions extending from both H1_DL2 and NHA dsRed cells. B indicates morphological 
alteration of H1_DL2 cells which now possess flattened granular membranes with lack of fusiform 
morphology. C indicates presence of cell debris from both cell types Scale bar: 25 µm 
 
Confocal visualization of the TNT model upon exposure to 0.5 µM vemurafenib (Figure 4.7) 
showed high frequency of homotypic and heterotypic TNT interactions between H1_DL2 and 
NHA dsRed cells. H1_DL2 cells exhibited slightly altered morphology from classic fusiform to 
flattened. Small amounts of nonadherent H1_DL2 cells and cell debris were also detected at this 
drug concentration. Confocal visualization of the TNT model upon exposure to 0.8 µM 
vemurafenib (Figure 4.8) showed larger amounts of floating non adherent cells, as well as increase 
in morphology alterations in larger populations of H1_DL2 cells, which exhibited flattened 
granular membranes. Morphological analyses of H1_DL2 cells also revealed distinct features of 
senescence induced by vemurafenib. A higher frequency of H1_DL2 initiated TNT interactions 
were also visible in the fields of view, as well as increased amounts of TNT clusters extending 












(Figure 4.9) showed reduced cell density of H1_DL2 cells and large amounts of floating cell 
debris. Higher number of TNT interactions by H1_DL2 cells compared to those of NHA dsRed 
cells were visualized in all fields of view. H1_DL2 cells also exhibited distinct shrinkage in cell 
morphology and non-adherence characteristic of apoptosis. High degree of senescence was also 
exhibited, with presence of distinct mechanotransducive stretching in several H1_DL2 cells. No 
alterations in cell morphology were detected in NHA dsRed cells, and cells maintained their 
multipolar epithelial morphology. Confocal visualization of the TNT model upon exposure to 1.5 
µM vemurafenib (Figure 4.10) showed low density of H1_DL2 cells and large degree of H1_DL2 
cell apoptosis. Adherent H1_DL2 cells were flat with granular membranes, with few visible 
spindle shaped appendages. High frequency of homotypic and heterotypic TNT initiations was 
detected from H1_DL2 cells. NHA dsRed cells exhibited slightly altered morphology, possibly 
due to initiation of cell senescence. Both cell populations exhibited emergence of TNT clusters on 
their cell surfaces. Large amounts of cell debris of both H1_DL2 and NHA dsRed cells were also 
apparent in all fields of view.  
 
4.4.1 H1_DL2 initiates higher relative percentage of TNT interactions with increasing drug 
concentrations 
 
Figure 4.11 Quantification of TNT interactions between H1_DL2 and NHA dsRed during the 8 
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hr, 24 hr and 33 hr timepoints of the study across selected vemurafenib drug concentrations (0.5 
μM, 0.8 μM, 1 μM and 1.5 μM). The experiment was carried out 2 times with the most 
representative results presented. 
 
The quantification of TNT interactions between H1_DL2 and NHA dsRed across selected 
vemurafenib drug concentrations during the 8th, 24th and 33rd hrs of the study is shown in Figure 
4.11. Quantification results of TNT interactions initiating from H1_DL2 and NHA dsRed revealed 
an increasing relative percentage of TNT interactions initiated by H1_DL2 across all 3 timepoints 
of the study with increasing drug concentrations. This increase was most pronounced across 0.5 – 
1 μM vemurafenib drug exposure (from around 22-74%). The relative percentage of TNT 
interactions initiated by NHA dsRed decreased across increasing drug concentration exposure and 
stayed relatively constant across 1-1.5 μM vemurafenib drug exposure. The relative percentage of 
TNT interactions initiated by NHA dsRed was the highest (78%) at the lowest vemurafenib drug 






















4.4.2 H1_DL2 initiates increasing relative percentage of heterotypic TNT interactions with 
NHA dsRed at increasing drug concentrations across all 3 timepoints of the study. 
 
Figure 4.12 Quantification of homotypic and heterotypic TNT interactions between H1_DL2 and 
NHA dsRed during the 8 hr, 24 hr and 33 hr timepoints of the study across selected vemurafenib 
drug concentrations (0.5 μM, 0.8 μM, 1 μM and 1.5 μM). The experiment was carried out 2 times 
with the most representative results presented. 
 
The quantification of homotypic and heterotypic TNT interactions between H1_DL2 and NHA 
dsRed across selected vemurafenib drug concentrations during the 8th, 24th and 33rd hrs of the study 
is shown in Figure 4.12. Quantification results showed an increase in the relative percentage of 
H1_DL2 initiated heterotypic TNT interactions (between H1_DL2 and NHA dsRed) with 
increasing drug concentrations (from around 16 – 44%). While the relative percentage of H1_DL2 
initiated TNT interactions strongly increased with increasing drug concentrations, a higher 
majority of these interactions were found to be heterotypic, and most pronounced in the range of 
0.8 – 1.5 μM vemurafenib drug exposure. The relative percentage of H1_DL2 initiated homotypic 
TNT interactions was also higher with increasing drug concentrations and across all 3 timepoints 
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of the study. There was a negligible difference in the relative percentage distribution of homotypic 
and heterotypic TNT interactions between H1_DL2 and NHA dsRed across 1-1.5 μM vemurafenib 
drug exposure.  
 
4.5 hBEC luc GFP and High Seeding Density of NHA dsRed forms Acceptable 
BBB Model for a period of 48 hrs 
hBEC lucGFP and concentrations of NHA dsRed were seeded in transwell inserts (as described in 
Section 3.4) and the TEER and FITC dye permeability of the resulting barrier formations were 









Figure 4.13B Comparison of TEER measurements in all BBB model barriers over 14 days   
 




TEER measurements were taken every 24 hrs until the barrier resistance values began to decrease 
significantly. As seen in Figures 4.13A and 4.14B, the barrier composed of hBEC lucGFP and 
high NHA dsRed exhibited the highest TEER values (about 50 Ohms.cm2) over the period of 14 
days. The TEER of the barrier remained relatively consistent from Day 8 to Day 10 of the study, 
which indicated its optimal use as an acceptable BBB model for 48 hrs. The barrier composed of 
hBEC lucGFP and low NHA dsRed exhibited the 2nd highest TEER values (about 45 Ohms.cm2) 
over the period of the study, and indicated a positive correlation between the seeding densities of 
NHA dsRed in association with hBEC lucGFP and barrier strength. The barrier composed of hBEC 
lucGFP only exhibited TEER values at a maximum of 42 Ohms.cm2. In contrast, the barriers 
composed of high NHA dsRed only and low NHA dsRed only exhibited maximum TEER values 
of 20 and 15 Ohms.cm2. This indicated that majority of the resistance provided by the hBEC 
lucGFP and high NHA dsRed barrier were due to hBEC lucGFP proliferation on the transwell 
membranes. None of the barrier models exhibited potential of recovering barrier strength after Day 
11. TEER values of blank transwell membranes were relatively consistent over the period of the 
study. The TEER values of the barrier models were backed by the results of the FITC dye 
permeability assay (Figure 4.14). The dye permeability assay was performed on the 7th day of 
TEER measurement (Day 7) to offer time for barrier formation and repeated 7 days later (Day 14). 
The barrier composed of hBEC lucGFP and high NHA dsRed exhibited the lowest FITC 
permeability on both days, which supported the previously reported TEER values. The barrier 
exhibited a permeability of about 4 µg/mL on Day 7, which was 24 hrs prior to its highest exhibited 
TEER value. The barrier composed of hBEC lucGFP and low NHA dsRed exhibited the 2nd lowest 
FITC permeability on both days, while barriers composed of high NHA dsRed only and low NHA 
dsRed only exhibited high FITC permeability on both days. It’s important to note that the barrier 
composed of hBEC lucGFP only was the only barrier model out of the 5 models which exhibited 
a higher FITC permeability on Day 7 than Day 14, owing to its slightly higher barrier strength on 
Day 14. Blank transwell membranes exhibited negligible differences in their FITC permeability 









4.5.1 hBEC lucGFP and NHA dsRed form confluent monolayers on apical and basal regions 





























Figure 4.15 Confocal visualization of barrier models hBEC lucGFP + High NHA dsRed (A1, A2, 
A3) and hBEC lucGFP + Low NHA dsRed (B1, B2, B3). Images captured on 20x objective in the 
X-Y plane. Confocal visualization of hBEC lucGFP + high NHA dsRed in the X-Z plane (C). 
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Scale bar: 50 µm 
 
Confocal visualization of hBEC lucGFP and NHA dsRed (both high and low) barriers (Figure 
4.15) revealed the formation of confluent layer of hBEC lucGFP on the apical region of the 
transwell membrane and the formation of confluent layer of NHA dsRed (both high and low) on 
the basal region of the transwell.  hBEC lucGFP exhibited geometrical direction of propagation, 
characteristic of endothelial monolayer formation. NHA dsRed presented as a dense cell 
population with overlapping cell growth. The positions of both cell layers were visibly 
distinguishable on confocal X-Z images and validated the ability of hBEC lucGFP and NHA dsRed 
to form strong barriers in cooperation with each other.  
 
4.6 Transmigration of H1_DL2 across BBB Model can be Evaluated at a Range 



















Figure 4.16 Confocal visualization of transmigrated H1_DL2 seeding densities across the BBB 
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model. A indicates transmigrated H1_DL2 cells of an initial seeding density of 5 x 103. B indicates 
transmigrated H1_DL2 cells of an initial seeding density of 1 x 104. C indicates transmigrated 
H1_DL2 cells of an initial seeding density of 5 x 104. D indicates transmigrated H1_DL2 cells of 
an initial seeding density of 1 x 105. Images captured on 10x objective. Scale bar: 100 µm 
 
Analyses of the images revealed visual evidence of an increasing number of migrated H1_DL2 
cells across the BBB model with increasing seeding densities. At the lowest seeded density of 
H1_DL2 (5 x 103), transmigrated H1_DL2 cells appeared as small green specks against the NHA 
dsRed cells present on the basal region of the BBB model barrier. At higher cell densities (1 x 104 
and 5 x 104), H1_DL2 cells appeared as larger clumps of green, possibly indicating transmigration 
of groups of MBM cells using the same route across the BBB model. At the highest seeded density 
(1 x 105 H1_DL2 cells), transmigrated H1_DL2 cells had spread across the basal region of the 
barrier and were difficult to evaluate quantitatively. Unfortunately, due to coronavirus-related time 
constraints, the number of transmigrated H1_DL2 cells across the BBB model could not be 
quantified and evaluated across the selected H1_DL2 seeded densities. However, it was still 
evident that the BBB model could be used to evaluate the transmigratory capacity of H1_DL2 cells 








Brain metastases remain to be a frequently daunting unmet medical challenge in patients with 
metastatic melanoma. Regardless of breakthroughs in neuroimaging, neurosurgery, radiotherapy, 
targeted therapies and immunotherapies, which have revolutionized BM management over the last 
decade 284, survival rates of diagnosed patients continue to be measured in months 285,286. Advances 
in MBM research are hindered for several reasons, including the difficulty of modeling metastatic 
cancer growth in the dynamic brain microenvironment and the complex nature of the disease 287. 
Current treatment strategies struggle to overcome effective drug penetration across the BBB 288, 
protection of secondary tumors within the brain metastatic niche 154,289 and development of tumor 
resistance a few months post treatment 290,291. With that in mind, there has also been a need to 
diverge research into investigating the distinctive characteristics of the brain in a more “systems 
biology” approach, to elucidate the interactions between the components of the central nervous 
system and how they give rise to the function and behavior of in vivo metastatic BM pathogenesis. 
 
In this thesis, we adopt that approach to reveal, for the first time, the presence of TNT interactions 
between MBM and NHA, as well as the dynamic nature of these interactions in the presence of 
anticancer drug treatment. We reveal our findings through the establishment of an in vitro 3D TNT 
interaction model that can be used ideally from 8 to 32 hrs to study TNT interactions between 
MBM and NHA. Furthermore, we also established an in vitro 3D BBB model with high resistance 
and low permeability, which can be employed ideally for a period of 72 hrs for evaluating BBB 
migration of MBM at a seeding density range of 5 x 103 – 5 x 104 cells.  
 
5.1 H1, HA and hBEC lucGFP exhibit Distinct Morphology and Strong 
Fluorescent Protein Expression in vitro  
The triangular and elongated fusiform shape of H1_DL2 (Figure 4.1 A1, A2, A3) resonated 
similarities with that obtained of melanocytes in vivo 292 as well as previous morphological studies 
conducted in our laboratory using the established brain metastasis cell line H1.  
 
The dense multipolar epithelial morphology with low stratification of NHA dsRed (Figure 4.1 B1, 
B2, B3) indicated similarities to contemporary characterizations of visualized astrocytes in vivo 
covering distinct regions of the CNS 293. However, it is important to note that astrocyte 
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morphology is highly dynamic in vivo, and differ in morphology and functional diversity based on 
their localization within the brain 294,295. Morphological analysis of in vitro NHA dsRed coincided 
with that described by Lange and colleagues of primary astrocyte in vitro cultures which form a 
contact inhibited monolayer with epitheloid like cells lacking synaptic contact and vascular 
elements. Furthermore, they suggested the coculturing of astrocytes as a means of addressing the 
absence of a dynamic microenvironment in vitro while still maintaining the advantages of 
monotypic astrocyte cultures 296.  
 
hBEC lucGFP cells showed spindle-shaped, elongated morphology characteristic of brain 
endothelial cells and non-overlapping cell growth upon formation of confluent monolayers. The 
qualitative results (Figure 4.1 C1, C2, C3) supported past studies which used the originating cell 
line (hCMEC/D3) to produce cell-based assays mimicking the human BBB in vitro  266,297,298. 
Further, the results are in line with descriptions provided by Weksler and colleagues, who also 
stated that the primary advantage of using this cell line was its representation of an easily grown, 
transferable and stable population of human microvascular cerebral endothelial cells capable of 
maintaining BBB phenotypes such as expression of junctional proteins, transendothelial electric 
resistance and restricted paracellular permeability to substances 299.  
 
The qualitative data obtained of all 3 cell lines individually indicated successful cell sorting of 
high fluorescent protein expression. It is important to mention that all cell lines were received for 
use in the thesis after transduction and cell sorting procedures had been completed, and future 
studies should consider that the transduction and cell sorting procedures could provide useful 
information of the characteristics of the individual cell lines.  
 
5.2 Cell Seeding Densities of 5 x 103 (1:1) of H1_DL2 and NHA dsRed cells yields 
Well-spaced, Uniform growth distribution of Cells, optimal for 8-36 hrs of 
Confocal Visualization of TNTs 
 
IncuCyte evaluation results (Figure 4.2) revealed that a cell seeding density of 5 x 103 H1_DL2 
and 5 x 103 NHA dsRed cells (1:1 ratio) provided a suitable degree of cell confluency within the 
field of view, uniform distribution of cells within the coculture monolayer plane and optimal 
frequency of visible cellular interactions. With a focus on a TNT interaction model development, 
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the results indicated an optimal timepoint at 8-36 hrs for attempting to visualize TNT interactions 
between H1_DL2 and NHA dsRed cells if they were present. While there has been a number of 
coculture studies for visualization of TNT interactions between 2 different cell populations 300–312, 
very little has been published to explain for selection of cell seeding densities in studies. Civita 
and colleagues justified the use of various coculture ratios of glioblastoma to astrocyte cells in 
their study to evaluate if both cell populations could grow together at 95% viability to establish 
direct contact 304. In contrast, our analysis supports the protocol established by Abounit and 
colleagues, who identified optimal confluency of cells as a key parameter to achieve good 
conditions for TNT formation and stated that high or low confluence of cells could impair TNT 
formations 278. The results also suggested an increasing frequency of visible cytoplasmic 
interactions between both cell populations within the established timepoint range (8-36 hrs), after 
which, cell populations grew too close to each other to visibly identify interactions. This was 
important for development of the TNT interaction model due to the 2 models of TNT interaction 
described in Section 1.10. Sowinski and colleagues identified the formation of TNT interactions 
between T cells after at least 4 mins of direct contact 272, while Staufer and colleagues identified 
passive TNT formation during protease mediated dense cell singularization 313. Both studies 
suggested the possibility of passive TNT generation during cell dislodgement, which reinforced 
the importance for optimal frequency of visible cellular interactions in the TNT model.  
 
5.3 H1_DL2 and NHA dsRed initiate Homotypic and Heterotypic TNT 
Interactions in Coculture 
 
As observed in Figure 4.3, TNTs emerging from NHA dsRed cells could clearly be seen travelling 
over the underlying H1_DL2 cells in the substratum to form 3 heterotypic interactions with 
surrounding H1_DL2 cell types. This unique feature of TNTs was first identified by Rustom and 
colleagues in the rat pheochromocytoma (PC12) cell line 203, which distinguishes them from other 
discovered cellular protrusions such as cytonemes 314, streamers 315 and nanopodia 316. Width 
measurements indicated confirmation of the identity of TNTs visualized, with all widths measured 
less than 1 µm. These results highlighted a key criterion distinguishing TNTs from intercellular 
bridges (widths > 1 μm) observed in cell cultures. Homotypic and heterotypic TNT interactions 
visualized demonstrated membrane continuity between connected cells. However, the 
identification of these TNT interactions as being open ended or close ended could not be 
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determined via confocal visualization, prompting the need for more sophisticated imaging 
techniques and TNT specific markers to improve TNT morphology visualization. Okafo and 
colleagues utilized scanning electron microscopy (SEM) techniques to obtain higher detection and 
resolution images of TNT mediated long range gap junctional communication in HIV infection 
317, while Sartori-Rupp and colleagues utilized correlative light- and cryo-electron microscopy 
approaches to distinguish the cytoskeletal structural identity of TNTs from filopodia 318. As 
observed in Figure 4.4, formation of TNT “clusters” was also detected in coculture visualization 
during the 24th hr of the study but were not included in the quantification since they were not seen 
to connect two or more cells. Interestingly, these TNT “clusters” were not detected among 
complete TNT interactions, and existing literature review does not provide much evidence of this 
phenomenon. It could be hypothesized that these clusters extend out of TNT initiating cells and 
disintegrate when a single TNT meets a target cell. Furthermore, the recent identification of 
“iTNTs”, or TNTs composed of several individual tunneling nanotubes, by Korenkova and 
colleagues 319 could suggest an explanation for formation of these clusters. Nevertheless, the use 
of more sophisticated imaging techniques as well as time lapse imaging is warranted to provide 
more accurate identification and function of these structures. Schiller and colleagues also utilized 
fixation techniques to preserve the formation of TNTs by the transmembrane MHC class III protein 
leukocyte specific transcript 1 (LST1) 320. The use of fixation techniques is highly debated in 
existing literature 217,278, owing to the fragility of TNT formations especially for in vivo tissue 
fixation. This promotes the need for improved in vitro model developments and suggested the 
introduction of gentle fixation techniques in future studies. Morphological alterations in H1_DL2 
were detected in the 33rd hour of the TNT interaction study (Figure 4.5). While this result may 
indicate the start of possible cell senescence, an alternate outcome was also suggested by Connor 
and colleagues, who showed that cancer cell-endothelial intercellular transport alters the 
phenotype of the recipient cells 321. However, this could not be further investigated within the 
timeframe of the study.  
 
The formation of homotypic TNT interactions was visualized in H1_DL2 in the 8th, 24th and 33rd 
hrs of the experiment. This indicated an initiation of intercellular conversation and the possible 
transfer of cellular cargo within the tumor cell population of the study. While further experiments 
are required to identify the “messages” being delivered among tumor cells, previous studies have 
demonstrated a correlation between tumor cell ability to form homotypic TNT interactions and a 
promotion of their aggressive cancer phenotype 322. Thayanithy and colleagues identified the 
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transfer of oncogenic miRNAs via TNTs between malignant ovarian tumor cells and their less 
metastatic counterparts 323. Furthermore, Osswald and colleagues also demonstrated a correlation 
between extended TNT interconnectivity among metastatic glioma cells and their poorer 
therapeutic response to radiotherapy 324. Ady and colleagues demonstrated a correlation between 
TNT interaction within malignant mesothelioma cells and a promotion in the expression of genes 
related to the disease invasion and metastasis 325. The formation of homotypic TNT interactions 
among varying histological grades of bladder cancer cells has also been demonstrated by Lu and 
colleagues to induce TNT mediated transfer of miRNA from most aggressive to least aggressive 
cells and promote cancer proliferation and motility 326. Building on existing evidence, it could be 
hypothesized that homotypic TNT interactions between H1_DL2 cells could be a means of 
promoting MBM metastasis, treatment resistance, proliferation, and invasion.  
 
The formation of heterotypic TNT interactions was also visualized between H1_DL2 and NHA 
dsRed 8th, 24th and 33rd hrs of the experiment. This indicated a simultaneous and possibly 
synchronous cellular communication between tumor cells and astrocytes within the coculture. 
While further experiments are required to elucidate the true nature of these conversations and the 
cellular cargoes transported between the two cell populations, previous studies have demonstrated 
the ability of TNT interactions between tumor and TME cells to induce the metastatic and invasive 
phenotype of the cancer. Hanna and colleagues demonstrated similar activity in in vitro cocultures 
of breast cancer cells and macrophages, where TNT mediated contacts from TME cells promoted 
the acquisition of invasive phenotypes in breast cancer in dependence of epidermal growth factor-
epidermal growth factor receptor (EGF-EGFR) pathway 327. Studies carried out by Pasquier and 
colleagues have also identified the transfer of mitochondria between TME endothelial and breast 
cancer cells via TNTs to possibly restore tumorigenic potential in cancer cells lacking 
mitochondrial DNA 328. Finally, similar studies carried out by Errede and colleagues identified the 
formation of TNTs evoked by endothelial cells and pericytes in the TME to promote 
vascularization and angiogenic potential in human glioblastoma cells 302. Therefore, based on 
existing evidence, it could be hypothesized that heterotypic TNT interactions between H1_DL2 
and NHA dsRed cells could be a means of promoting MBM proliferation, invasiveness, metastasis 
and angiogenic ability.  
 
5.3.1 NHA dsRed initiates higher relative percentage of homotypic and heterotypic TNT 




Quantification results revealed a higher percentage of homotypic and heterotypic TNT interactions 
initiating from NHA dsRed cells across all 3 timepoints of the study, compared to H1_DL2 
(Figure 4.6). The results indicated that majority of MBM tumorigenicity was directed by TNT 
interactions initiating from NHA dsRed during the established timepoints of the study. Similar 
results were identified by Zhang and Zhang, who quantified a higher percentage of TNT initiations 
from rat primary astrocytes compared to glioma cells in coculture studies 329. As discussed 
previously, TNT interactions between tumor cells and components of the TME can induce 
metastatic and invasive phenotypes of cancer through the transport of mitochondria, miRNAs, and 
other substances via TNT interactions. Wang and colleagues reported the induction of TNTs in 
astrocytes which were dependent on p53, EGFR, Akt, PI3K and mTOR activations, and stated the 
possibility of TNT formations being a characteristic feature of cells dealing with cellular stress 
and reducing self-metastatic development 330. It is also interesting to mention that studies have 
revealed a synergistic cooperation between TNTs and exosomes. Thayanithy and colleagues 
demonstrated the induced enhancement of TNT formation in human mesothelioma cells by 
exogenous tumor exosomes 331. Therefore, it could also be hypothesized that homotypic and 
heterotypic TNT interactions between H1_DL2 and NHA dsRed could also be dictated and guided 
by potent chemotactic exosome stimuli released by MBM to promote pathway dysregulations. 
Homotypic interactions between NHA dsRed cells could indicate a possible transfer of healthy 
mitochondria and mRNA to damaged or dying NHA dsRed cells, to maintain TME stability. 
Furthermore, cancer cells are recognized to influence cells in the TME to promote pathways that 
support their growth and development 217. Polak and colleagues reported a signal from leukemia 
cells in acute lymphoblastoma to bone marrow cells resulting in the release of tumor survival 
promoting cytokines 332. This could also indicate a deeper degree of MBM manipulation of the 
TME, through the promotion of intercellular mitochondria and miRNA distribution among NHA 
dsRed cells in the TME to sustain tumor proliferation, angiogenesis, and growth. The experiments 
provide a new insight into the relationship between MBM and the TME, and the relation of the 
outcome in sustaining MBM development and maintenance. However, whether TNT mediated 
interplay between MBM and NHA dsRed results in a net decrease or increase of tumor metastatic 
potential is a possibility that requires further investigation. The associated fragility of TNT 
interactions, which limits their lifetimes to minutes 195,201, should be taken into account in future 
quantification studies. While our quantification experiment was conducted twice, a further trial 
followed by statistical analyses (such as a t-test) is also necessary. Furthermore, the 
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generalizability of our results is limited by the efficiency of manually counting TNTs within the 
selected fields of view. The utilization of software for automated counting of TNTs, such as that 
developed by Hodneland and colleagues for the identification of TNT formations in PC12 cells 
333, could improve the accuracy of quantification results in future studies. 
 
5.4 H1_DL2 initiates Higher Frequency of Homotypic and Heterotypic TNT 
Interactions at Increasing Vemurafenib Concentrations 
 
Confocal visualization revealed a higher frequency of homotypic and heterotypic TNT interactions 
initiating from H1_DL2 at increasing vemurafenib concentrations across all 3 timepoints of the 
study. This frequency was most pronounced across 0.8 – 1.5 μM vemurafenib drug exposure 
(Figures 4.8, 4.9, 4.10). The results indicated that TNT interactions initiated by MBM cells were 
more prevalent upon exposure to anticancer drug treatment in the TME microenvironment and 
demonstrated a correlation between increasing TNT formation in MBM and rising vemurafenib 
concentrations. Recently, Zoetemelk and colleagues also reported similar results, by describing an 
enhancement of TNT formation in colorectal cancer cells with increasing vemurafenib 
concentration. They concluded that this rise in TNT formations was associated with increasing 
therapy resistance 334. Interestingly, 40 – 60% of metastatic colorectal cancer cases are associated 
with BRAF mutations 335. Our results coincide with several studies reporting the formation of more 
TNTs by tumor cells in an adaptive response to therapeutic stress 217,336. Filippova and Nabors 
recently reported the formation of homotypic and heterotypic TNT formations by glioma cells to 
promote tumor heterogeneity and survival against treatment resistance337. Civita and colleagues 
reported TNT formation between astrocytes and glioblastoma cells to be crucial in mediating 
tumor chemo resistance, and provided a means of transfer of cellular contents between cells under 
stress 304. Based on existing evidence, it can be speculated that MBM cells could utilize TNT 
formations to transfer undamaged mitochondria, useful substances, or energy between cell 
populations in the TME to promote tumorigenesis and survival. Furthermore, Wang and Gerdes 
reported the use of TNT based intercellular communication by PC12 cells to prevent tumor 
apoptosis through the delivery of mitochondria and the dispersal of cytotoxic factors 203. Altered 
morphology of H1_DL2 cells was also visualized at increasing vemurafenib concentrations 
(Figures 4.7, 4.8, 4.9, 4.10). This analysis supports the theory that anticancer drugs induce 
morphological changes in target tumor cells 338–341. Dratkiewicz and colleagues identified similar 
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results in vemurafenib resistant melanoma cell lines, with resistant cells being more spread out, 
displaying a spindle-like appearance, and presenting highly pronounced stress fibers compared to 
parental cell lines. Furthermore, they suggested cell spreading characteristics to be associated with 
alterations in focal adhesion protein levels in treated melanoma cells 342. A recent study by 
Tabolacci and colleagues confirmed that BRAF inhibitor resistant cells presented a more 
aggressive phenotype opposed to parental cell lines, with higher production of interleukin-8, 
vascular-endothelial growth factor (VEGF), interferon-γ, CD147/basigin, and metalloproteinase 2 
(MMP-2) 343. Based on existing evidence, it can be speculated that MBM cell lines develop altered 
morphology in response to vemurafenib treatment in the process of cellular cytoskeletal 
reprogramming which favors their proliferation, survival, and invasiveness. Confocal visualization 
of the TNT model upon exposure to 0.8-1.5 µM vemurafenib (Figures 4.8, 4.9, 4.10) showed 
reduced cell density of H1_DL2 cells and large amounts of floating cell debris and non-adherent 
cells. These results suggest a reduction in H1_DL2 proliferation capacity as well as exhibition of 
cell senescence in response to increasing vemurafenib concentrations. In line with existing 
research, previous studies have revealed BRAF mutated cell lines to express dependent and 
heterogenous phenotypes in response to BRAF inhibitors such as vemurafenib, dabrafenib and 
trametinib nearing the IC50 concentrations of these cell lines 344–346. Fallahi-Sichani and 
colleagues reported initial cell growth arrest consistent with MAPK proliferation activity and a 
rise in apoptosis in 40-60% of BRAF mutated melanoma cells responding to BRAF inhibitor 
treatment. Furthermore, they identified a subpopulation of treated cells to overcome drug mediated 
cell cycle arrest and exhibit decelerated cell division opposed to drug “naïve” cells 345. Frick and 
colleagues and Hata and colleagues further reported a reduction in maximal drug effect on MBM 
cells exhibiting such drug adapted slow cycling characteristics, and suggested this behavior to 
contribute to development of genetically distinct drug resistant clones 347,348. Based on this existing 
research evidence and our obtained results, it can be hypothesized that BRAF inhibitor resistant 
MBM cell lines coordinate their adaptive responses with TNT coordination between TME cells 
such as astrocytes to promote treatment resistance and cell survival. 
 
 
5.4.1 H1_DL2 initiates increasing relative percentage of homotypic and heterotypic TNT 
interactions at increasing drug concentrations across all 3 timepoints of the study. 
Quantification results revealed a higher percentage of homotypic and heterotypic TNT interactions 
initiating from H1_DL2 at increasing drug concentrations across all 3 timepoints of the study 
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(Figure 4.12). In line with the results discussed in Section 5.4, this indicated further evidence that 
TNT interactions initiated by MBM cells increased upon exposure to anticancer drug treatment in 
the TME microenvironment and demonstrated a correlation between increasing TNT formation in 
MBM and rising vemurafenib concentrations. Similar quantification results were obtained in a 
recent study by Valdebenito and colleagues, who evaluated the number of TNTs induced in 
glioblastoma cells in response to chemotherapeutic drug temozolomide. They found a sharp 
percentage increase in the number of TNTs induced in treated glioblastoma in a time dependent 
manner, resonating with our results in MBM cell line.  The shift in prevailing relative percentage 
of homotypic and heterotypic TNT interactions from NHA dsRed to H1_DL2 was most 
pronounced in the 0.8 – 1.5 µM vemurafenib concentration range, indicating a shift in H1_DL2 
behavior in coordination with NHA dsRed nearing vemurafenib concentrations presenting IC50 
values in H1 monoviability studies previously conducted in our lab (with reported IC50 of 0.87 
µM). In line with existing research evidence, these results support our previously mentioned 
hypothesis of an adaptive response promoted by BRAF inhibitor resistant MBM cell lines to 
maintain their tumorigenic potential and drug resistance development during anticancer treatment 
strategies. Furthermore, they promote studies repurposing existing drugs towards TNT inhibition 
and investigating TNT inhibitors as a novel class of cancer therapeutics 349. While our 
quantification experiment was conducted twice, a further trial followed by statistical analyses 
(such as a t-test) is also necessary. 
 
5.5 hBEC lucGFP and High Seeding Density of NHA dsRed forms Acceptable 
BBB Model for a period of 48 hrs 
 
Our seeded barrier composed of hBEC lucGFP and high NHA dsRed exhibited the highest TEER 
values (about 50 Ohms.cm2) over the period of 14 days (Figures 4.13A, 4.13B). The TEER of the 
barrier remained relatively consistent from Day 8 to Day 10 of the study, which indicated its 
optimal use as an acceptable BBB model for 48 hrs. Our functional data results also indicated that 
majority of the resistance provided by the hBEC lucGFP and high NHA dsRed barrier were due 
to hBEC lucGFP proliferation on the transwell membranes and supported existing research 
evidence of astrocyte layers possessing low electrical resistance 350. In contrast, Aasen and 
colleagues utilized similar techniques with 75000 hCMEC/D3 cells and 2500 human brain 
astrocyte cells (SC-1800) to prepare in vitro BBB model with a maximum TEER resistance of 
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around 28 Ohms.cm2 266. The range of TEER values exhibited by model barriers utilizing different 
seeding densities of NHA dsRed suggested that our BBB model could be easily regulated, and 
barriers of higher resistance could be produced using higher seeding densities of hBEC lucGFP 
and NHA dsRed than those used in our study. This modifiable parameter indicated the usability of 
our BBB model to generate barriers possessing resistances close to that expected of the in vivo 
BBB (about 2000 Ohms.cm2) 351. However, it is important to note that the sophisticated 
physiological conditions of the in vivo BBB possesses several properties (such as circulatory flow 
and shear stress) that are complex to precisely reproduce in vitro 352,353. The utilization of 
astrocytes to promote TEER in both contact and non-contact in vitro coculture barrier models with 
endothelial cell cultures has been demonstrated in numerous studies, involving murine, porcine 
and human cells 354–358. Studies conducted by Abbott reported the capability of astrocytes to release 
humoral agents such as glutamate, adenosine triphosphate (ATP), taurine, tumor necrosis factor 
alpha (TNFα) and interleukin 1β IL-1β to modulate the junctional regulation of the BBB and 
function in barrier induction and maintenance over short time periods 180. In contrast, the 
introduction of triple culture systems utilizing human and rat endothelial cells, astrocytes and 
pericytes have demonstrated higher TEER values than corresponding endothelial cell/astrocyte 
BBB models 354,359,360, and suggest a promising avenue of improvement in our currently 
established BBB model.  
 
Our established BBB model composed of hBEC lucGFP and high NHA dsRed also exhibited the 
lowest FITC permeability on both days of dye permeability evaluation (Figure 4.14), which 
provided further functional evidence of model barrier tightness and integrity. The use of FITC 
extravasation in determining the permeability of in vitro BBB models is supported in various 
published protocols 361,362. Both TEER and FITC evaluation suggest the use of our established 
model as a standard system for estimating MBM proliferation and pathogenesis across BBB, as 
well as transport parameters of drug delivery into CNS. Furthermore, the use of peptides, such as 
K16ApoE, which promote BBB permeability and consequently, improved drug delivery in 
targeted MBM treatment could be further investigated 266 using this model.  
 
5.5.1 hBEC lucGFP and NHA dsRed form confluent monolayers on apical and basal regions 
of the transwell membrane 
Confocal visualization of hBEC lucGFP and NHA dsRed (both high and low) barriers (Figure 
4.15) in both X-Y and X-Z planes validated the ability of hBEC lucGFP and NHA dsRed to form 
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strong barriers in cooperation with each other. Our localization analysis indicated the capability of 
both cell populations to form coordinated confluent spread on both apical and basal regions of the 
transwell membrane. Czupalla and colleagues suggested the integration of expression analysis 
techniques (via qRT-PCR and Western blotting) to promote confidence in functional data and to 
monitor gene expression of barrier related proteins such as ZO-1 and occludin 363. Furthermore, 
the use of immunocytochemistry techniques to implement immunofluorescence staining of 
junctional proteins cadherin, ZO-1, claudin and actin could provide a higher degree of localization 
information for BBB phenotype in future studies 185,364,365.  
 
5.6 Transmigration of H1_DL2 can be Evaluated at a Range of Cell Seeding 
Densities across Established in vitro BBB Model 
Confocal analyses revealed localization evidence of an increasing number of transmigrated 
H1_DL2 cells across our in vitro BBB model with increasing seeding densities (Figure 4.16). Our 
results also revealed H1_DL2 clumping upon barrier transmigration at higher seeded densities (1 
x 104 and 5 x 104 cells) and indicated collective utilization of transmigratory routes across the BBB 
by MBM. Similar results were obtained by Fazakas and colleagues, who suggested that 
transmigrated melanoma cells attracted other melanoma cells to migrate across endothelial cell 
layers at the same site. They further reported the ability of melanoma cells to initiate disruption of 
inter-endothelial junctions and migrate via paracellular pathways across the BBB 185. Dratkiewicz 
and colleagues also reported a more aggressive migratory and invasive phenotype in vemurafenib 
resistant cell lines compared to their parental counterparts 342. While our initial plan was to quantify 
the number of transmigrated H1_DL2 cells across the BBB model to evaluate this characteristic, 
due to coronavirus-related time constraints, we were unable to do so. Furthermore, confocal 
images of transmigrated H1_DL2 at 1x105 seeded densities revealed formation of continuous layer 
of H1_DL2 cells across basolateral region of barrier that was difficult to quantify, indicating the 
optimal use of our established BBB model for evaluating transmigration of low seeded densities 
of H1_DL2. The integration of expression analysis techniques in future studies could provide 
further information of the factors and molecules involved in the transmigration process 366,367, as 
well as utilization of more sophisticated microscopy techniques to evaluate contact between 





5.7 Future Perspectives 
The use of targeted therapies has provided transformative evidence in the treatment of MBM as 
well as improved patient survival outcomes. However, the lack of therapies equally effective 
against extracranial and cranial diseases has called for refined therapeutic strategies that account 
for both the biology of the brain microenvironment and the melanoma metastatic cascade. The 
urge for reduced needs of experimental animals and lower costs have called for the development 
of in vitro models for use prior or parallel with in vivo models. The emergence of 3D in vitro 
models which incorporate patient derived tissues/cells and allow longitudinal measurements to 
mimic the TME, have bridged the divide between oversimplified 2D systems and unrepresentative 
animal models. Our established 3D in vitro TNT interaction and BBB models have provided novel 
information and deeper understanding of MBM interactions with the TME. The next logical step 
would be refining these models to better represent the complexities of the in vivo environment and 
to integrate techniques (as previously discussed) into these models to better identify spatial and 
temporal tumor interactions with system cells, as well as identify molecular players responsible 
for orchestrating these interactions. Identifying the processes by which MBM cells communicate 
with components of the BME to avoid therapeutic elimination will expose new vulnerabilities and 
pave the way for more effective treatment strategies. Till date, the identification of TNTs is based 
on their morphological characteristics, and the morphological diversity of these structures has 
instituted ambiguity to the nomenclature and literature review of these structures. The unification 
of established terminology for TNTs is of dire need, and the maturation of methods for studying 
homotypic and heterotypic TNT interactions initiated by MBM and their role in the pathogenesis 
of the disease could significantly lead the next generation of novel MBM prognostic markers and 
provide novel targets for cancer therapy. The identification of TNT specific biomarkers could aid 
in understanding the cargo being distributed between MBM and the BME, as well as provide vital 
information on cell signaling pathway dysregulation mechanisms. Furthermore, the development 
of small molecule inhibitors which target specific upregulated proteins involved in MBM invasion 
and migration across the BBB could turn the tide against the aggressive phenotype developed by 
MBM, especially those which are BRAF inhibitor resistant. We eagerly anticipate the extent to 
which these 3D in vitro models develop soon, and their incorporation as mainstream cancer 
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